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ABSTRACT 
 
 
 
SKEWED X-CHROMOSOME INACTIVATION IN  
JUVENILE IDIOPATHIC ARTHRITIS AND RHEUMATOID 
ARTHRITIS 
 
Chigdem Aydın Mustafa 
PhD in Molecular Biology and Genetics 
Supervisor: Prof. Dr. Tayfun Özçelik 
June, 2012 
 
 
There is a female predominance in most of the autoimmune diseases, and it 
is thought to play an important role in identifying the etiological factors. Sex 
hormones, microchimerism and environmental factors are thought to be 
responsible. Nowadays, it is proposed that a disturbance in mosaicism of 
females may cause autoimmune disease development. Recently, in our lab, 
an association between extremely skewed X-chromosome inactivation 
(XCI) patterns and female predisposition to autoimmunity was identified in 
Turkish population. In this study, we hypothesized that skewed XCI might 
play a role in the disease development of Juvenile idiopathic arthritis (JIA) 
in Turkish, and Rheumatoid Arthritis (RA) in French population. Therefore, 
XCI status of healthy individuals and patients diagnosed with JIA and RA 
were genotyped by analyzing androgen receptor (AR) locus by methylation 
sensitive HpaII digestion followed by PCR. Extremely skewed XCI was 
observed in a significant proportion of JIA (OR: 11.33; P=0.0008) in 
Turkish population, and RA (OR: 7.6; P=0.005) in French population. In 
conclusion, our results suggest that extremely skewed XCI may play an 
important role in autoimmune disease pathogenesis.  
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ÖZET 
 
 
 
 
JÜVENİL İDİYOPATİK ARTRİT VE ROMATOİD ARTRİT 
HASTALIĞINDA X KROMOZOMU İNAKTİVASYONU SAPMASI 
 
 
Chigdem Aydın Mustafa 
Doktora Tezi, Moleküler Biyoloji ve Genetik 
Tez Danışmanı: Prof. Dr. Tayfun Özçelik 
Haziran, 2012 
 
 
Dünya çapında en sık rastlanan hastalık olan otoimmün hastalıkların çoğu 
kadınlarda daha sık görülmektedir. Bunun nedeni olarak cinsiyet 
hormonları, mikrokimerizm ve çevresel etkenler sorumlu tutulmaktadır. Son 
zamanlarda X kromozomu inaktivasyonu (XCI) sapması da buna neden 
olarak gösterilmektedir. Yakın zamanda laboratuarımızda gerçekleştirilen 
çalışmalarda, Türk popülasyonunda, X kromozomu inaktivasyonu sapması 
ve kadınların otoimmün hastalıklara yatkınlığı arasında bağlantı 
kurulmuştur. Bu çalışmada X kromozomu inaktivasyonuna bağlı mozaik 
yapının bozulmasının otoimmün hastalık etiolojisinde rol alabileceği 
hipotezi test edilmiştir. Bu nedenle Türk popülasyonunda jüvenil idiyopatik 
artrit (JIA) ve Fransız popülasyonunda romatoid artrit (RA) hastaları ve 
sağlıklı bireyler genotiplenmiştir. XCI statüsünü belirlemek için androjen 
reseptörü (AR) geni metillemeye duyarlı HpaII enzimi ile analiz edilmiştir. 
Türk popülasyonunda  JIA (OR: 11.33; P=0.0008) ve Fransız 
popülasyonunda RA (OR: 7.6; P=0.005) hastalarında XCI’nda aşırı sapma 
gözlenmiştir. Sonuçlarımız XCI ile otoimmün hastalık gelişimi arasında bir 
ilişki olabileceği görüşünü desteklemektedir.        
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CHAPTER I 
INTRODUCTION 
1.1. Immune System 
 
The immune system protects the body from infectious agents and the 
damage that they cause, with the help of variety of effector cells and 
molecules, which are able to differentiate self from non-self antigens. There 
are two mechanisms that immune system use for determination of 
foreigners, innate and adaptive immunity. Innate immunity is evolutionarily 
old and present in both plants and animals (Hoffman et al., 1999). The 
pattern recognition receptors in the innate immunity recognize the 
conserved molecular patterns, pathogen-associated molecular patterns 
(PAMPs), that are shared by many of the organisms (Medzhitov and 
Janeway, 2000). However, adaptive immunity provides specific recognition 
of pathogens by pathogen-specific adaptor proteins. Although the adaptive 
immune system can recognize the foreign antigens with the help of 
rearrangement of large variety of receptor gene segments, it is also 
responsible for allergy, rejection of tissue grafts, and autoimmunity 
(Janeway and Medzhitov, 2002). 
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1.2. Autoimmunity 
 
The immune system is able to discriminate self antigens and foreign 
antigens. While lymphocyte development, lymphocytes are tested against 
self tolerance by two mechanisms, central tolerance and peripheral 
tolerance. The immature lymphocytes that recognize self antigens are 
eliminated by apoptosis in the central lymphoid organs, which are thymus 
for T cells, and bone marrow for B cells. The tolerance induced in this stage 
is called central tolerance. If this lymphocyte escapes from test of self 
tolerance, it can be still removed in peripheral tissues. There are three 
mechanisms of elimination of self reactive lymphocytes: 1) deletion, 
lymphocytes are killed by induction of apoptosis; 2) anergy, functional 
unresponsiveness; and 3) suppression by regulatory T cells (Goodnow et al., 
2005). Upon activation of self reactive lymphocytes that could escape from 
the tolerance, an immune response that causes autoimmune disease 
development is induced against its own cells and tissues (Rioux and Abbas, 
2005).   
 
Autoimmune diseases affect 3-5% of the population in US, Asia and Europe 
(Cooper et al., 2009). Autoimmune diseases are classified by clinicians 
either systemic, or organ specific. In systemic autoimmune diseases, such as 
systemic lupus erythematosus (SLE), multiple organs might be affected, 
while in organ specific, such as hashimoto's thyroiditis (HT), only one organ 
might be affected (Table 1.1).  
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Table 1.1 Systemic and organ specific autoimmune diseases 
Type  Name of the disorder  Affected organs/tissues 
Systemic Rheumatoid arthritis   Joints, skin, less commonly lung 
  SLE     Skin, joints, kidneys, heart, brain, 
red blood cells 
  Scleroderma    Skin, intestine, lung 
  Sjogren’s syndrome   Salivary glands, tear glands, joints 
Organ specific Type I diabetes mellitus   Pancreas islets 
Hashimoto’s thyroiditis,   Thyroid 
Grave’s disease 
Celiac disease, Crohn’s disease  GI tract 
Primary biliary cirrhosis   Liver 
  Vitiligo    Skin 
 
 
   
1.2.1. Causes of autoimmunity 
 
The mechanisms of autoimmune diseases remain to be fully elucidated. 
There are multiple factors that are thought to play role in autoimmune 
disease development, such as genetic susceptibility, environmental factors, 
and infectious agents. Nowadays epigenetic factors are also thought to play 
role in autoimmunity.  
 
Different human leukocyte antigen (HLA) alleles, which are encoded by 
major histocompatibility complex (MHC), were found to be associated with 
autoimmune diseases. However, upon linkage analyses and gene association 
studies, new candidate genes – non-HLA genes, such as AIRE, FOXP3, 
PTPN22, CTLA4, and STAT4 were identified (Gregersen and Behrens, 
2006). 
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For a long time, infections were proposed to be an environmental factor for 
autoimmune disease induction. The pathogens might induce autoimmunity 
by several mechanisms such as, molecular mimicry, cell apoptosis or 
necrosis, polyclonal activation of autoreactive lymphocytes (Kivity et al., 
2009). Upon infection, cell apoptosis is induced, and the deficiency of the 
clearance of the apoptotic cell leads to nuclear material accumulation, which 
may cause autoimmunity (Schulze et al., 2008).  
 
 
1.2.1.1.  Genes associated with autoimmunity 
1.2.1.1.1. AIRE 
 
AIRE (autoimmune regulator) is a transcription factor that regulates the 
expression of some self antigens in thymic epithelial cells, which play role 
in the negative selection of central tolerance. It was first found to be mutated 
in autoimmune polyendocrine syndrome (APS-1), in which autoantigens 
attack multiple organs and the skin (Bjorses et al., 1998).  
 
When the AIRE is mutated, the self antigens are not presented by MHC 
molecules, leading to the escape of T cells specific for these, and attack the 
target tissues (Liston et al., 2003; Anderson et al., 2005).  
 
 
1.2.1.1.2. CTLA4 
 
CTLA4 (Cytotoxic T lymphocyte antigen 4) is an inhibitory receptor, which 
regulates T cell proliferation. Association of CTLA4 with several 
autoimmune diseases, such as Grave’s disease (GD), type 1 diabetes (T1D), 
and rheumatoid arthritis (RA) was reported (Ueda et al.,2003, Gregersen 
and Behrens, 2006).  CTLA4 function both negatively and positively. It 
inhibits T cell activity upon binding to its ligands CD80 and CD86 on 
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antigen presenting cells (APC), while activates regulatory T cells, which 
play an important role on autoimmunity (Gregersen and Behrens, 2006).   
 
 
1.2.1.1.3. FOXP3 
 
FOXP3 (forkhead box P3) encodes a transcription factor of the forkhead 
family. It was shown that inhibition of Foxp3 in mouse induces systemic 
autoimmune disease because of the absence of regulatory T cells (Fontenot 
et al., 2003). Similar to the mouse model, FOXP3 mutation causes IPEX 
(immune dysregulaton, polyendocrinopathy, enteropathy, X-linked 
syndrome) in humans (Wildin et al., 2002). 
 
 
1.2.1.1.4. PTPN22 
 
PTPN22 (protein tyrosine phosphatase, non-receptor type 22) encodes a 
lymphoid specific phosphatase (LyP). It was shown that a SNP 1858C→T, 
which changes the amino acid from an arginine (R) to a tryptophan (W) at 
codon 620, is associated with T1D, RA, SLE and GD (Begovich et al., 
2004; Bottini et al., 2004, Gregersen and Behrens, 2006).  
 
 
1.2.1.1.5. STAT4 
 
STAT4 (signal transducer and activator of transcription 4) encodes a 
transcription factor that play role in the expression of genes that are 
important in immune response. An association of an intronic SNP and SLE 
and RA was first found by Remmers and colleagues in 2007.  
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1.2.1.2.   Molecular Mimicry 
 
One of the environmental factors that cause autoimmunity is molecular 
mimicry. In molecular mimicry, the foreign peptide that share similar 
sequence with self-antigen can cause cross-reaction. Upon activation of 
autoreactive T or B cells, this may cause to break of self-tolerance, causing 
autoimmunity. Molecular mimicry was shown to play role in some 
autoimmune diseases, such as SLE and systemic sclerosis (SSc) (Doria et 
al., 2008; Randone et al., 2008; Reviewed in Lin et al., 2011). 
 
 
1.2.1.3. Epigenetics 
 
Although higher disease concordance of autoimmune diseases in 
monozygotic twins relative to dizygotic twins or other family members 
indicates a genetic contribution, the incomplete concordance of the disease 
in some monozygotic twins indicate that some additional factors of 
environment  also play a role. Recently, it was shown that environmentally-
induced epigenetic changes may alter the DNA methylation pattern, 
resulting in the loss of self-tolerance because of aberrant gene expression 
(Strickland et al., 2008; reviewd in Hewagama and Richardson, 2009).  
 
 
1.2.2. Female predominance in autoimmunity 
 
For a long time, it is well known that there is a female predominance in 
most of the autoimmune diseases (Whitacre, 2001).  In Table 1.2, 
female:male ratio is represented in several autoimmune diseases. The 
reasons of this predominance remain to be fully elucidated, but there are 
several explanations such as hormonal differences, reproductivity, 
microchimerism and skewed X-chromosome inactivation (XCI).  
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Table 1.2. Female to male ratio for selected autoimmune diseases (Selmi, 
2008) 
Disease    female:male ratio 
 
Addison’s disease    0.8-2.4:1  
Autoimmune chronic hepatitis  7:1  
Graves’ disease    7:1  
Hashimoto’s disease    5-18:1  
Multiple sclerosis    2:1  
Primary biliary cirrhosis   10:1  
Rheumatoid arthritis    2:1  
Sjogren’s syndrome   9:1  
Systemic lupus erythematosus  9:1  
Systemic sclerosis    5:1 
 
 
 
1.2.2.1. Hormones 
 
T and B cells express estrogen receptors (ER) and androgen receptors (AR), 
indicating the possible role of sex hormones in immune response.  Also, it 
was indicated that immune response in females varies as their hormonal 
status changes. In rheumatoid arthritis (RA) and multiple sclerosis (MS) 
symptoms of the disease are decreased during the pregnancy where estrogen 
level is high, while in SLE, they are increased or remain same (Nalbandian 
and Kovats, 2005). However, studies have failed to demonstrate direct role 
of the hormone – but not disregarding their importance, indicating some 
other factors on gender difference (Invernizzi et al., 2009).  
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1.2.2.2 Microchimerism 
 
Another difference between males and females is the reproductivity.  During 
pregnancy, maternal and fetal cells are exchanged, leading to 
microchimerism in the mother. Microchimerism was first found to be 
associated with systemic sclerosis (SSc) by Nelson et al., in 1998 and 
confirmed by Artlett et al., in 1998. Although the mechanism is not clear, it 
cannot explain the female predominance, because of the patients that do not 
give birth (Invernizzi et al., 2009).  
 
 
1.2.2.3. Skewed X-chromosome inactivation 
 
The sex chromosomes differ in males and females. Males are hemizygous 
for X-chromosome, while females inactivate one of their X-chromosomes 
for dosage compensation. Therefore, females are mosaics for X-
chromosome inactivation (XCI), as a result of random inactivation of one of 
the X-chromosomes. Disturbed XCI was used to explain the female 
predominance in autoimmune diseases by Kast in 1977 and developed by 
Stewart in 1998. According to Kast and Stewart, the disturbance of the 
mosaicism could lead to differences of the antigen presentation, causing 
autoimmunity. Although Chitnis et al. was failed to show the association of 
several autoimmune diseases with skewed XCI in 2000, the association was 
found with SSc, autoimmune thyroid disease (AITD), and pre-eclampsia 
(Ozbalkan et al., 2005; Ozcelik et al., 2006; Uz et al., 2007; Uz et al., 
2008).    
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1.3. X-inactivation 
1.3.1. History 
 
X-chromosome inactivation was first proposed by Lyon in 1961 to be the 
dosage compensation mechanism in mice. Upon several unexpected results 
in her analysis of mutations affecting the coat color of female mice, she 
suggested that one of the two X-chromosomes in each cell of a female is 
inactivated randomly leading females to be mosaics. She suggested that the 
X-inactivation event occurred early in development that causes formation of 
large patches of different color (Lyon, 1961).  
 
After these proposals, a hypothesis came from Ohno and colleagues, who 
demonstrated, first in mice then in humans, each Barr body (Barr et al., 
1949) was a single X-chromosome, and the other X was euchromatic like 
the autosomes (Ohno et al., 1960, Ohno et al., 1961).  
 
 
1.3.2. Mechanism 
 
There are different mechanisms for sex development in different species. 
The presence of a Y chromosome is necessary for male development in 
mammals, while in fruit flies and worms, it is dependent on the ratio of the 
X-chromosome to autosomal chromosomes. In order to compensate the 
dosage problem between males and females, different species have 
developed different mechanisms. In Drosophila melanogaster, XY males 
increase the expression of their single X-chromosome, while in 
Caenorhabditis elegans, XX hermaphrodites reduce each X chromosome’s 
expression by half, in order to achieve similar transcription levels in XO 
males. However, in mammals, females inactivate one of the X chromosomes 
(Pontier and Gribnau, 2011).   
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There is a random XCI in eutherian mammals, while in marsupials, X-
chromosome inactivation is imprinted - the X-chromosome coming from the 
father is always inactivated (Cooper et al., 1971). However, it was shown 
that eutherian mammals also have imprinted XCI, which is limited to extra-
embryonic tissues-the placenta. In four-cell stage of mouse embryos, 
paternally-derived X-chromosomes undergo an early imprinted inactivation, 
leaving the maternal X-chromosome active only. The extraembryonic 
tissues retain this early imprinted inactivation, but in the early blastocyst, 
initial imprinted X-inactivation is reversed in the inner cell mass that give 
rise to the embryo. Each of these cells then independently and randomly 
inactivates one of the X-chromosomes irreversibly, leading to mosaicism 
(Huynh and Lee, 2004).  The existence of imprinted XCI in humans remains 
controversial. Recently, it was shown that XCI in human extraembryonic 
tissues is also random (Moreira de Mello et al., 2010). 
 
X-inactivation is a multistep process including counting, choice, silencing 
and maintenance. In the counting step, the X-chromosome number relative 
to autosomes is determined, while in choice, X-chromosome that remain 
active (Xa) is chosen. Silencing is then initiated and spread on the inactive 
X-chromosome (Xi), and maintained in daughter cell lineages (Chow et al., 
2005). 
 
XCI is regulated by the X-inactivation center (XIC), which is mapped to 
Xq13. XIC consists of several genes such as, XIST, TSIX, and XITE (Brown 
et al., 1991; Lee et al., 1999; Kalantry 2011). XIST (X-inactive specific 
transcript), which is a non-coding RNA, is expressed from the future Xi. 
During the inactivation process, XIST is regulated by TSIX, which is the 
antisense complementary transcript of XIST. TSIX, which is regulated by 
XITE, is expressed from Xa and prevents XIST expression in the Xa 
(Kalantry. 2011).  
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1.4. Autoimmune disorders that were selected in this study 
1.4.1. Rheumatoid Arthritis (RA) 
 
Rheumatoid arthritis (RA) is an inflammatory disease that causes joint 
destruction, resulting in pain, stiffness and swelling of peripheral joints 
(Aletaha et al., 2010). RA affects 1% of the population, worldwide, with a 
female predominance (Gabriel and Michaud, 2009). There are multicellular 
inflammation in the joint, including infiltration of lymphocytes and 
granulocytes into the articular cartilage, and proliferation of macrophages. 
These processes not only cause pain and stiffness but also joint destruction 
and reduction of bone density (Nandakumar and Holmdahl, 2006).  
 
  
1.4.1.1. Classification 
 
In 1987, criteria for RA were developed by the American Rheumatology 
Association (ARA). According to these criteria four of the seven features 
are needed to be present: morning stiffness, arthritis of 3 or more joint areas, 
arthritis of hand joints, symmetric arthritis, rheumatoid nodules, positive 
serum rheumatoid factor (RF) and radiographic changes (Arnett et al., 
1988).   Recently, new criteria was developed and introduced by American 
College of Rheumatology/European League Against Rheumatism 
(ACR/EULAR). According to the new criteria, patients that have a point 
score of 6 or higher are called RA patient. The point scores were developed 
by ACR/EULAR. The points are given according to four areas of diagnosis: 
joint involvement, serological parameters, acute-phase reactants and 
duration of symptoms (Aletaha et al., 2010). 
 
 
 
12 
 
1.4.1.2. Prevalence, incidence 
 
During last two decades, several incidence and prevalence studies of RA 
have been reported. According to these studies, the frequency changes with 
the different ethnic and racial groups. The prevalence of RA is between 
0.5% and 1% and the incidence of RA decreased from 61.2 per 100,000 
population in the period 1955–1964 to 32.7 per 100,000 in the period 1985–
1994 (Gabriel and Michaud, 2009). In south European countries, the 
occurrence of RA is relatively lower according to north European and north 
American countries (Alamanos and Drosos, 2005). 
 
 
1.4.1.3. Causes 
 
The cause of the RA is not well known, but genetic and environmental 
factors are thought to be involved. Smoking is the most reported risk factor 
for RA (Silman et al. 1996, Harrison 2002). It is reported that genetics 
determines 50-60% of susceptibility, severity and phenotype of RA 
(MacGregor et al., 2000; Deighton et al., 1989). Monozygotic twins have 
concordance rates of 15%, while dizygotic twins have rates of 4% (Silman 
et al., 1993; Aho et al., 1986). 
 
   
1.4.1.3.1. Associated genes       
 
In 1978, HLA-DRB1 was first to be associated with RA (Stastny, 1978). 
Later on, shared epitope common to all HLA-DRB1 alleles were found to be 
associated with RA in different populations (Imboden, 2009). 
 
In a large scale screening of 16,000 non-synonymous SNPs, PTPN22 
R620W SNP was found to be associated with RA (Begovich et al., 2004). 
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Like PTPN22, CTLA-4 negatively regulates T-cell activation (Sharpe and 
Freeman, 2002). A SNP of CTLA-4 was found to be associated with RA in 
German (Seidl et al., 1998), Japanese (Yanagawa et al., 2000), and British 
(Vaidya et al., 2002) populations. Recently STAT4 was also found to be 
associated with RA in different populations (Remmers et al., 2007; Korman 
et al., 2008).  
 
  
1.4.1.3.2. Antibodies 
 
RA is characterized by the presence of autoantibodies, such as rheumatoid 
factor (RF) and anti-cyclic citrullinated peptide (CCP) antibody. Although 
RF was never proved to cause arthritis in experimental systems, it was the 
only antibody that is used for classification of RA (Arnett et al., 1988). 
However, anti-CCP was found to be present in 70% of RA patients, and rare 
in healthy poeple (Agrawal et al., 2007). In the new classification criteria, 
anti-CCP is also included for diagnosis of RA (Aletaha et al., 2010). 
 
 
1.4.2. Juvenile Idiopathic Arthritis (JIA) 
 
Juvenile idiopathic arthritis (JIA), which is the inflammation (cellular 
damage) of the synovium (the lining of joints), is the most prevalent 
pediatric rheumatic disease that is seen in children with onset before 16 
years of age. JIA patients have swollen, painful joints, which may be stiff 
and difficult to move. (Cuccurullo, 2004).  
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1.4.2.1. Classification 
 
Juvenile idiopathic arthritis (JIA) term (Petty et al., 1998; Petty et al., 2003; 
Petty et al., 2004) was first proposed in 1994 and later revised in 1997.It is 
now used instead of the American term ‘juvenile rheumatoid arthritis’ 
(JRA) as defined by American College of Rheumatology (ACR) and the 
European classification ‘juvenile chronic arthritis’ (JCA) as defined by the 
European League Against Rheumatism (EULAR) (Wood et al., 1978). The 
American and European classifications of the disease were confusing (Table 
1.3), and was difficult to use them interchangeably (disease duration is 6 
weeks for ACR, while it is 12 weeks for EULAR). In order to improve 
research and treatment, the International League Against Rheumatism 
(ILAR) unified the criteria, using the term ‘juvenile idiopathic arthritis’. The 
word ‘idiopathic’ means ‘of unknown cause’.  
 
 
 
Table 1.3. Comparison of the classification systems of arthritis in children 
 
 
 Classification        ACR     EULAR           ILAR 
____________     _____                    _______                                  _____ 
 Designation     JRA       JCA                          JIA 
 
     
  Types             Systemic    Systemic            Systemic 
  Pauciarticular      Pauciarticular                         Oligoarticular 
  Polyarticular       RF-negative polyarticular         RF-negative 
            polyarthritis 
                                                          RF-positive polyarticular         RF-positive  
            polyarthritis 
 Psoriatic           Psoriatic 
 JAS             Enthesitis-related 
                     Undefined     
 
 
ACR=American College of Rheumatology; EULAR=European League against 
Rheumatism; ILAR=International League of Associations for Rheumatology; 
JRA= juvenile rheumatoid arthritis; JCA= juvenile chronic arthritis; JIA= juvenile 
idiopathic arthritis; JAS= juvenile ankylosing spondylitis (Petty et al., 2003). 
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1.4.2.2. Types 
 
According to ILAR, the subtypes of JIA are oligoarticular JIA, which may 
be persistent or extended, polyarticular rheumatoid factor (RF)–negative 
JIA, polyarticular RF-positive JIA, systemic JIA, enthesitis-related arthritis 
(ERA), psoriatic JIA, or a classification of “other JIA” when the criteria for 
more than one subtype of JIA or none of the criteria were met (Petty et al., 
1998). 
 
 
1.4.2.2.1. Oligoarticular JIA 
 
Oligoarthritis, which is the most common type that affect about 50% of all 
children with JIA, is mostly seen in females. This term is used when there 
are four or fewer affected joints during the first 6 months of disease. 
According to the ILAR classification, children who have psoriasis/a family 
history of psoriasis, a human leukocyte antigen (HLA) B27-associated 
disease in a first-degree relative, and a positive rheumatoid factor (RF) test 
are excluded from the oligoarthritis category (Petty et al., 1998). 
 
This form of JIA is the only one that is not seen in adults, and characterized 
by asymmetric arthritis, early age of onset (before 6 years of age), female 
predominance, and high frequency of positive antinuclear antibodies 
(ANAs).  
 
According to the ILAR classification, oligoarthritis subtype is divided to 
persistent oligoarthritis, in which the disease consists of four or fewer joints, 
and extended oligoarthritis, in which arthritis extends to more than four 
joints after the first 6 months of disease (Petty et al., 1998; Ravelli et al., 
2007). 
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1.4.2.2.2. Polyarticular JIA 
 
Polyarticular arthritis affects 35% children with JIA, more girls than boys. 
This kind of JIA usually involves small joints of the hands and feet. 
Polyarticular JIA is often symmetrical.  There are two types of polyarticular 
JIA: rheumatoid-factor-positive and rheumatoid-factor-negative polyarthritis 
(Cuccurullo, 2004; Ravelli et al., 2007).  
 
 
1.4.2.2.2.1. Rheumatoid-factor-positive polyarthritis 
 
This disease, comprises 10% of all patients with JIA, and is characterized by 
age of onset greater than 11 years of age with female predominance 
(Cuccurullo, 2004). Although it is same as adult RF-positive rheumatoid 
arthritis, the disease phenotype between children and adults is different as 
the children’s skeleton is still growing. It is mainly seen in adolescent girls 
(Cuccurullo, 2004; Ravelli et al., 2007).  
 
It is characterized as a symmetrical polyarthritis and affects small joints of 
the hands and feet (Ravelli et al., 2007).   
 
 
1.4.2.2.2.2. Rheumatoid-factor-negative polyarthritis 
 
It is the most heterogeneous subtype (Ravelli et al., 2007). It affects 25% of 
all patients with JIA (Cuccurullo, 2004). There are at least three subsets of 
RF-negative polyarthritis. The first form resembles early-onset 
oligoarticular juvenile idiopathic arthritis because of the asymmetric 
arthritis, and early age of onset (Martini, 2003; Ravelli et al., 2007). The 
second subset is similar to adult onset RF-negative rheumatoid arthritis, 
because of the characteristics of symmetric synovitis of large and small 
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joints. The third form is known as dry synovitis. This subset is often poorly 
responsive to treatment and could follow a destructive progress (Ravelli et 
al., 2007).  
 
 
1.4.2.2.3. Systemic JIA 
  
It usually begins in early childhood. Researchers sometimes call this Still’s 
disease. This type accounts for about 10-20% of cases of JIA. It affects both 
boys and girls almost equally. It is characterized by suddenly occurring 
fever. Anemia and weight loss may also occur (Ravelli et al., 2007).  
 
 
1.4.2.2.4. Enthesitis-related arthritis 
 
Enthesitis-related arthritis, which is characterized by the association of 
enthesitis (inflammation of the entheses) and arthritis, mainly affects male 
patients after the age of 6 years. The joints of the lower extremities are 
affected. It resembles oligoarthritis because of the hip involvement (Petty et 
al., 1998; Petty et al., 2003; Ravelli et al., 2007). 
 
 
1.4.2.2.5. Psoriatic arthritis 
 
According to ILAR, in order to diagnose juvenile psoriatic arthritis, arthritis 
and psoriatic rash need to be present. If a rash is absent, dactylitis (sausage-
shaped swelling of the fingers and toes that can be painful), nail pitting and 
the presence of psoriasis in a first degree relative must be present. The 
symptoms are similar to the subset of RF-negative polyarthritis, and 
oligoarthritis (Petty et al., 1998; Ravelli et al., 2007). 
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1.4.2.2.6. Undifferentiated arthritis 
 
This subtype includes the patients that do not fulfil the inclusion criteria for 
any category (Petty et al., 2004; Ravelli et al., 2007).  
 
 
1.4.2.3. Prevalence and incidence 
 
The incidence and the prevalence of the disease differ among different 
ethnicity. It has an incidence of 2–20 cases per 100 000 population and a 
prevalence of 16–150 cases per 100 000 population (Ravelli et al., 2007). 
 
The frequency of the subtypes differs. There is female predominance, except 
in the systemic and enthesitis-related arthritis (Table 1.4). In systemic 
arthritis female-male ratio is equal. In enthesitis-related arthritis, there is 
male predominance.   
 
Table 1.4 International League of Associations for Rheumatology (ILAR) 
categories of juvenile idiopathic arthritis 
 Frequency Onset age Sex ratio 
Systemic arthritis 4-17% Throughout 
childhood 
F=M 
Oligoarthritis 27-56% Early childhood F>>>M 
Rheumatoid factor 
(+) polyarthritis 
2-7% Late childhood F>>M 
Rheumatoid factor (-
) polyarthritis 
11-28%  F>>M 
Enthesitis related 
arthritis 
3-11% Late childhood M>>F 
Psoriatic arthritis 2-11%  F>M 
Undifferentiated 
arthritis 
11-21%   
Adopted from (Ravelli et al., 2007) 
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1.4.2.4. Causes 
 
Although the cause of JIA is not well-understood, it is believed that JIA is 
caused by a combination of genetic and environmental factors such as viral 
or bacterial infections that may trigger the autoimmune process (Cuccurullo, 
2004).  
 
 
1.4.2.4.1. Associated Genes 
 
There are both MHC-associated and Non-MHC genes that are found to be 
associated with JIA.  The class I gene, HLA-B27, was the first HLA 
association found in JIA. It is found that HLA-B27 is a risk factor for 
oligoarthritis, particularly in older male patients (Rachelefsky et al., 1974; 
Reviewed in Borchers et al., 2006).  
 
SNPs in PTPN22 and CTLA4 were also found to be associated with JIA in 
different populations (reviewed in Phelan et al., 2006). 
 
 
1.4.2.4.2. Antibodies 
 
Although wide variety of autoantibodies has been described in  JIA patients, 
RF and antinuclear antibodies (ANA) are routinely used to provide 
serological support for the diagnosis of JIA.  
 
ANA are detected in ~30–50% of patients with JIA (Berntson et al., 2003) 
the prevalence vary from 38% to 85% in oligoarthritis, ~30–50% in 
polyarthritis and 0–17% in systemic onset disease (Al-Matar et al., 2002; 
Moroldo et al., 2004).  
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In more recent studies, anti-CCP antibodies were reported in 77% of 
patients with JIA overall, 93% in RF-negative polyarthritis, 84% in 
oligoarthritis and 62% in systemic arthritis (Borchers et al., 2006). 
 
 
1.5.  Aim and Strategy 
 
Most of the autoimmune diseases have high female predominance 
(Whitacre, 2001). Although the female prevalence is often attributed to the 
effect of estrogen, it is stated that other sex differences might have as much 
or more relevance to autoimmune disease, that is X-inactivation (Stewart, 
1998).  Recently, it has been shown that high proportion of scleroderma, 
AITD and pre-clampsia patients has extremely skewed X-inactivation in 
their blood cells (Ozbalkan et al., 2005; Ozcelik et al., 2006; Uz et al., 
2007; Uz et al., 2008).   
 
RA is an autoimmune disease, with unknown cause. Like other autoimmune 
diseases there is female predominance. Hormonal levels and pregnancy-
related microchimerism was previously hypothesized to play role in 
autoimmunity. However our group and others observed that skewed XCI 
could be a factor (Ozbalkan et al., 2005; Brix et al., 2005; Ozcelik et al., 
2006; Uz et al., 2007; Uz et al., 2008). Therefore we included the pediatric 
form of RA, JIA, in which the onset of the disease is before puberty, 
therefore hormonal status would not be effective. There is also a female 
predominance in JIA. 
 
Here we hypothesize that skewed XCI might play a role in the pathogenesis 
of JIA and RA.  In order to test our hypothesis, we analyzed the methylation 
status of a highly polymorphic CAG repeat in the androgen receptor (AR) 
gene.  In this study we used JIA patients within the subgroups that have 
female predominance: oligoarthritis and polyarthritis from Turkish 
population, and RA from French population. 
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CHAPTER II 
MATERIALS AND METHODS 
2.1. MATERIALS 
 
2.1.1. PEDIATRIC SAMPLES 
 
2.1.1.1. Turkish Children Control Samples 
 
In this study, 211 healthy, unrelated Turkish children with no history of 
autoimmune disorders or cancer were involved.  The mean age at analysis 
was 13±4 (mean±SD). Informed consent was obtained from all subjects (or 
legal guardians of subjects who had not reached age of majority). The ethics 
committee of the participating institutions approved the study protocol.  
 
 
2.1.1.2. Turkish Juvenile Idiopathic Arthritis Patients 
 
Caucasian children diagnosed with juvenile idiopathic arthritis (n=81) were 
included in this study. All patients fulfilled the International League of 
Associations for Rheumatology diagnostic criteria for juvenile idiopathic 
arthritis (Petty et al. 2004). The mean±SD age of the patients was 10±5 
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years, and the mean age at the time of disease onset was 6±4 years. 21 of the 
patients were diagnosed with polyarthritis, while 60 were having 
oligoarthritis. Informed consent was obtained from all subjects (or legal 
guardians of subjects who had not reached age of majority). The ethics 
committee of the participating institutions approved the study protocol.  
 
 
2.1.2. ADULT SAMPLES 
2.1.2.1. French Control Samples 
 
Healthy, unrelated French females (n=100) with no history of autoimmune 
disorders or cancer were involved in this study. Informed consent was 
obtained from all subjects. The ethics committee of the participating 
institutions approved the study protocol. 
 
 
2.1.2.2. French Rheumatoid Arthritis Patients 
 
French females diagnosed with rheumatoid arthritis (n=86) were involved.  
Informed consent was obtained from all subjects. The ethics committee of 
the participating institutions approved the study protocol. 
  
 
 
2.1.2.3. Turkish Adult Control Samples 
 
For determination of frequency of PTPN22 genotypes in Turkish population 
68 unrelated healthy women were genotyped. Informed consent was 
obtained from all subjects. The ethics committee of the participating 
institutions approved the study protocol. 
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2.1.2.4. Turkish Systemic Sclerosis Patients 
 
For determination of frequency of PTPN22 genotypes in Turkish population 
71 SSc patients were enrolled in the study. The mean age of the patients was 
47 years. Informed consent was obtained from all subjects. The ethics 
committee of the participating institutions approved the study protocol.  
 
 
2.1.2.5. Turkish Autoimmune Thyroid Disease Patients 
 
In order to determine the frequency of PTPN22 genotypes 104 AITD 
patients were enrolled in the study.  The mean±SD age of the patients was 
49±14 years.  Informed consent was obtained from all subjects. The ethics 
committee of the participating institutions approved the study protocol.  
 
 
2.1.3. CHEMICALS, REAGENTS AND ENZYMES 
2.1.3.1. Primers 
 
The primers used in polymerase chain reaction (PCR) were purchased from 
IONTEK (Istanbul, Turkey). 
 
 
The primer sequences for AR are:   
RS6,  5'- GTCCAAGACCTACCGAGGAG -3'; 
   RS7,  5'- CCAGGACCAGGTAGCCTGTG -3' 
 
The primer sequences for PTPN22 are:    
PTPN22F, 5’-GATAATGTTGCTTCAACGGAATTTA -3’; 
PTPN22R 5’- TCACCAGCTTCCTCAACCACA -3’ 
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2.1.3.2. Enzymes 
 
Taq DNA polymerase enzymes and the restriction digestion enzymes XcmI, 
RsaI and methylation sensitive HpaII were purchased from MBI Fermentas 
(Amherst, NY, USA). 
 
 
2.1.3.3. Thermal cyclers 
 
For PCR reactions, the thermal cycler The GeneAmp System 9600 and 2400 
(Perkin-Elmer, USA) were used. 
 
 
2.1.3.4. Standard Solutions and Buffers 
 
1X TAE (Tris-acetic acid-EDTA):   40mM Tris-acetate, 
2 nM EDTA, pH 8.0 
 
Ethidium bromide:   10mg/ml in water  
(stock solution) 
30 ng/ml (working solution) 
 
 
Agarose gel loading buffer (6X):   15% ficoll 
0.05% bromophenol 
0.05% xylene cyanol 
 
Acrylamide:bisacrylamide (30%):   29.5 gr acrylamide 
0.44 gr bisacrylamide 
ddH2O to 100 ml 
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2.1.3.5. Chemicals and Reagents 
 
Table 2.1. Chemicals, reagents, and kits used in this study 
 
Reagent/Chemical    Company      
Agarose     Basica LE, EU    
Acetic acid     Sigma, St Lois, MO, USA  
Acrylamide     Sigma, St Lois, MO, USA 
Ammonium persulfate   Carlo Elba, Milano, Italy 
Bisacrylamide    Sigma, St Lois, MO, USA 
Bromophenol blue    Sigma, St Lois, MO, USA 
dNTPs     MBI Fermentas, Amherst, NY, USA 
EDTA     Carlo Elba, Milano, Italy 
Ethanol     Merck, Frankfurt, Germany 
Ethidium bromide    Sigma, St Lois, MO, USA 
Nucleospin® Blood Kit   Macherey-Nagel Duren, Germany 
TEMED     Sigma, St Lois, MO, USA 
Tris-Base     Bio-Rad, CA, USA 
 
 
 
2.1.3.6. Nucleic Acids 
 
As a DNA marker, pUC Mix8 was used, which is purchased from MBI 
Fermentas (Amherst, NY, USA) (Figure 2.1).  
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Figure 2.1. Sizes of the fragments of PUC mix marker, 8, and appearance 
on both agarose and polyacrylamide gel electrophoresis (MBI Fermentas 
web site) 
 
 
2.2. METHODS 
2.2.1. Sample Collection 
 
Venous blood that was obtained from controls and patients were collected in 
EDTA-containing tubes. They were divided into 1 ml aliquots in 1.5 ml 
eppendorf tubes. 200 μl of blood was used for DNA isolation; the remaining 
bloods were stored at -80
o
C for later use. 
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2.2.2. Determination of X chromosome inactivation status 
 
For dosage compensation in mammals, females randomly inactivate one of 
their X-chromosome, maternal or paternal (Lyon et al., 1961). The 
inactivation initiates upon transcription of XIST RNA from the X-
chromosome that will be inactivated. The untranslated XIST RNA coat the 
X-chromosome that it is produced and with the help of histone 
modifications, such as hypermethylation of CpG islands (Wolf et al., 1984; 
Heard and Disteche, 2006). HpaII is a methyl sensitive restriction enzyme, 
which recognizes CpG dinucleotides. Therefore, X-linked genes that contain 
HpaII recognition sites and silences during inactivation process can be used 
for determination of X-chromosome inactivation. Allen et al. first used 
androgen receptor (AR), which has highly polymorphic CAG repeats, in 
order to determine the XCI pattern (Allen et al., 1992).  In this assay, the 
DNA is digested with HpaII and the region that contains highly 
polymorphic CAG repeats flanked by restriction enzyme recognition site is 
amplified by PCR (Figure 2.2). After amplification only the inactive allele 
would give a product as the active one would be digested by HpaII. 
Therefore, in women informative for CAG repeat, methylation patterns of 
maternal and paternal X chromosomes can be identified.  
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>ref|NC_000023.9|NC_000023:66680599-66860844 Homo sapiens 
chromosome X, reference assembly 
 
GGGAAAAAGGGCCGAGCTAGCCGCTCCAGTGCTGT ACAGGAGCCGAAGGGACGCACCACGCCAGCCCCA 
 
GCCC GGCTCCAGCGACAGCCAACGCCTCTTGCAGCGCGGCGGCTTCGAAGCCGCCGCCC GGAGCTGCC 
 
CTTTCCTCTTCGGTGAAGTTTTTAAAAGCTGCTAAAGACTCGGAGGAAGCAAGGAAAGTGCCTGGTAGGA 
CTGACGGCTGCCTTTGTCCTCCTCCTCTCCACCCCGCCTCCCCCCACCCTGCCTTCCCCCCCTCCCCCGT 
CTTCTCTCCCGCAGCTGCCTCAGTCGGCTACTCTCAGCCAACCCCCCTCACCACCCTTCTCCCCACCCGC 
CCCCCCGCCCCCGTCGGCCCAGCGCTGCCAGCCCGAGTTTGCAGAGAGGTAACTCCCTTTGGCTGCGAGC 
GGGCGAGCTAGCTGCACATTGCAAAGAAGGCTCTTAGGAGCCAGGCGACTGGGGAGCGGCTTCAGCACTG 
CAGCCACGACCCGCCTGGTTAGGCTGCACGCGGAGAGAACCCTCTGTTTTCCCCCACTCTCTCTCCACCT 
CCTCCTGCCTTCCCCACCCCGAGTGCGGAGCCAGAGATCAAAAGATGAAAAGGCAGTCAGGTCTTCAGTA 
GCCAAAAAACAAAACAAACAAAAACAAAAAAGCCGAAATAAAAGAAAAAGATAATAACTCAGTTCTTATT 
TGCACCTACTTCAGTGGACACTGAATTTGGAAGGTGGAGGATTTTGTTTTTTTCTTTTAAGATCTGGGCA 
TCTTTTGAATCTACCCTTCAAGTATTAAGAGACAGACTGTGAGCCTAGCAGGGCAGATCTTGTCCACCGT 
GTGTCTTCTTCTGCACGAGACTTTGAGGCTGTCAGAGCGCTTTTTGCGTGGTTGCTCCCGCAAGTTTCCT 
TCTCTGGAGCTTCCCGCAGGTGGGCAGCTAGCTGCAGCGACTACCGCATCATCACAGCCTGTTGAACTCT 
TCTGAGCAAGAGAAGGGGAGGCGGGGTAAGGGAAGTAGGTGGAAGATTCAGCCAAGCTCAAGGATGGAAG 
TGCAGTTAGGGCTGGGAAGGGTCTACCCTCGGCCGCCGTCCAAGACCTACCGAGGAGCTTTCCAGAATCT 
 
GTTCCAGAGCGTGCGCGAAGTGATCCAGAACCC GGGCCCCAGGCACCCAGAGGCCGCGAGCGCAGCACC 
 
TCCC GGCGCCAGTTTGCTGCTGCTGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCA 
 
GCAGCAGCAGCAGCAGCAGCAGCAAGAGACTAGCCCCAGGCAGCAGCAGCAGCAGCAGGGTGAGGATGGT 
 
TCTCCCCAAGCCCATCGTAGAGGCCCCACAGGCTACCTGGTCCTGGATGAGGAACAGCAACCTTCACAGC 
 
CGCAGTCGGCCCTGGAGTGCCACCCCGAGAGAGGTTGCGTCCCAGAGCCTGGAGCCGCCGTGGCCGCCAG 
CAAGGGGCTGCCGCAGCAGCTGCCAGCACCTCC GGACGAGGATGACTCAGCTGCCCCATCCACGTTGTC 
 
CCTGCTGGGCCCCACTTTCCCC GGCTTAAGCAGCTGCTCCGCTGACCTTAAAGACATCCTGAGCGAGGC 
 
CAGCACCATGCAACTCCTTCAGCAACAGCAGCAGGAAGCAGTATCCGAAGGCAGCAGCAGCGGGAGAGCG 
AGGGAGGCCTCGGGGGCTCCCACTTCCTCCAAGGACAATTACTTAGGGGGCACTTCGACCATTTCTGACA 
ACGCCAAGGAGTTGTGTAAGGCAGTGTCGGTGTCCATGGGCCTGGGTGTGGAGGCGTTGGAGCATCTGAG 
TCCAGGGGAACAGCTTCGGGGGGATTGCATGT ACGCCCCACTTTTGGGAGTTCCACCCGCTGTGCGTCC 
 
 
Figure 2.2.   The sequence of AR, exon 1, downloaded from 
http://www.ncbi.nlm.nih.gov. The region amplified by PCR, the HpaII 
recognition sites and CAG repeat regions are shown.  
 
 
2.2.2.1. DNA Isolation 
 
The DNA isolation was carried out from 200 μl venous blood via 
Nucleospin® Blood kit (Macherey-Nagel Inc., PA, USA) according to 
manufacturer’s instructions. The remaining bloods were stored at -80oC for 
later use. After isolation, DNA was stored at 4
 o
C. The quantity of DNA 
samples were measured using nanodrop. Ratio of 260/280 reading of 1.8 ± 
0.2 was accepted as high quality DNA. The integrity of DNA samples were 
controlled by using 1% agarose gel electrophoresis. 
RS7 (Reverse Primer) 
CAG Repeats 
RS6 (Forward Primer) 
RsaI 
RsaI 
HpaII HpaII 
HpaII 
HpaII 
HpaII 
HpaII 
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2.2.2.2. Restriction Enzyme Digestion 
 
Two sets of reactions were prepared for each subject in restriction digestion 
protocol. Both sets contain 150-250 ng genomic DNA, 1X reaction buffer 
and 2 Units of RsaI. RsaI is a restriction enzyme with the recognition sites 
outside the PCR product. It digests active and inactive X alleles equally, and 
was used to improve the PCR. The only difference between these two sets is 
the presence of methylation sensitive restriction enzyme HpaII in the tube 
labeled as “digested (D)” (8 Units per 20 μL reaction). The tubes that do not 
contain HpaII were labeled as “undigested (U)”. Both reaction sets were 
completed to a final volume of 20 μL with deionized water. Restriction 
digestion reaction tubes were incubated at 37°C overnight. One control male 
sample that was cytogenetically verified as 46, XY was involved in this 
study as a control for complete digestion. 
 
 
2.2.2.3. Polymerase Chain Reaction (PCR) 
 
For each sample, two PCR were performed. Tubes that contain restriction 
digestion product of undigested reaction (without HpaII) as a template were 
labeled as “U”, and the tubes containing the product of digested reaction as 
a template were labeled as “D”.  PCRs were carried out in a total volume of 
25 μL.  Restriction digestion products were amplified with 10 pmol of each 
primers, 0.12 mM of dNTP, 1X Taq polymerase buffer, 1.0 mM MgCl2, and 
1 Unit Taq polymerase.  
 
In order to amplify the desired region on AR locus, 94°C 5 min initial 
denaturation step was followed by 30 cycles of 94°C for 30 sec 
(denaturation), 58°C for 30 sec (annealing), 72°C for 30 sec (extension) 
amplification step. Final extension was performed at 72°C for 5 min.  
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2.2.2.4. Agarose Gel Electrophoresis 
 
PCR products were run in the 1.5% agarose gel by using 1X TAE. Agarose 
was completely dissolved in 1X TAE electrophoresis buffer to required 
percentage in microwave and ethidium bromide was added to final 
concentration of 30ng/ml. The samples were loaded onto agarose gel with 
1/5 volume of loading buffer. The gel was run in 1X TAE at 100V for 30 
minutes at room temperature. 
 
 
2.2.2.5. Polyacrilamide Gel Electrophoresis (PAGE) 
 
The working PCR products were resolved by using 8% PAGE. In order to 
prepare PAGE, 30% acrylamide:bisacrylamide solution (29:1) was mixed 
with 10X TAE, 10 % Ammonium persulfate (APS), and TEMED and 
ddH2O. 10 μL from each sample was loaded and each gel was run at 15W 
for 2 hours. The gels were stained with EtBr for 5 min and destained in 
ddH2O for 5 min.  
 
 
2.2.2.6. Densitometric Analysis 
 
Densitometric analyses of the bands were performed twice for each sample 
using the MultiAnalyst version 1.1 software. The skewing ratio was 
calculated according to the formula in figure 2.3.  A corrected ratio (CrR) 
was calculated by dividing the ratio of the predigested sample (upper/lower 
allele) by the ratio of the non-predigested sample for normalization of the 
ratios that were obtained from the densitometric analyses. The use of CrR 
compensates for preferential amplification of the shorter allele when the 
number of PCR cycles increases (Delforge et al., 1995). A skewed 
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population is defined as a cell population with greater than 80% expression 
of one of the AR alleles. This corresponds to CrR values of <0.25 or >4. 
 
 
 
                       D1(U1+U2) 
Skewing ratio =  
                             2U1(D1+D2) 
 
Figure 2.3.   The formula for calculation of skewing ratio 
 
 
2.2.3. Determination of frequency of PTPN22 genotypes 
 
PTPN22 encodes lymphoid protein tyrosine phosphatase (LYP), which 
suppresses T-cell activation by bind to negative regulatory kinase Csk. More 
common allele 1858C can binding Csk, while 1858T does not (Bottini et al., 
2004).  1858C→T SNP, which is in the first proline-rich motif in human 
LYP, is on exon 14 of PTNP22 gene.  The C > T transition creates a 
restriction site for XcmI (figure 2.4). Therefore, in order to identify the 
polymorphism, PCR amplified fragment is digested by XcmI. 
 
 
 
 
 
 
 
 
 
 
 
 
U1=intensity of upper allele of undigested sample 
U2=intensity of lower allele of undigested sample 
D1= intensity of upper allele of digested sample 
D2= intensity of lower allele of digested sample 
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>ref|NG_011432.1| Homo sapiens protein tyrosine phosphatase, 
non-receptor type 22 (lymphoid) (PTPN22), RefSeqGene on 
chromosome 1 
 
TTATTATTATTATTTTTTGAGACGGAGTGTCCTGCTGCCACCCAGGCTGGAATGCAGTGGTGCAATCTCGGCTCAC
TGCAAGCTCTGCCTTCCGGGTTCACGCCATTCTCCCACCTCAGCCTCCCGAGTAGCTGGGACTACAGGGGCCCGCC
ACCACGCCCGGCTAATGTTTTGTGTTTTTAGTAGAGACACGGTTTCACCACGTTAGCCAGGATGGTTTCGATCTCC
TGACCTTGTGATCTGCCCGCCTCGGCCTCCGAAAGTGCTGGGATTACAGGCGTGAGCCACCGCGCCCAGCCCTACT
TTTGAGCTTTTAAAACAATAAATGTTAAAGAATAAGCAAAAACCTCCTGGGTTTGTACCTTAAGAGAATTTATTTT
GCTTTTTCCTTGAATGAACAAGTGTCAACTTTACTGATAATGTTGCTTCAACGGAATTTAAATATAAATTATGGTA 
 
AATTTATATTTAATATTAGAATATAAGAATTTCCTTTGGATTGTTCTAATTAACAATTGTTACAATATTTTTGACA
TTTTGGATAGCAACTGCTCCAAGGATAGATGATGAAATCCCCCCTCCACTTC CTGTACGGACACCTGAATCATTT 
 
ATTGTGGTTGAGGAAGCTGGTGAGTACAGTTCAGTAAGTATAAAATAAAGTGTGGGATGGGCATGGTGGCTCATGC 
 
CTTTAATTCCAGCACTTTGGGAAGCTGATGTGTGAGCCTTGAGTTTGAGGAGTTCATTGAGGCCAGGAGTTCAAGA
CTAGCCTGCGCAACATAGTGAGACCTCATCTCTAATTTTTTTTTTTTAATTTAGCAGAGCAATAGCAGCATGCATG
TGTAGTCCCAACTATTTGGATGGTGGAGGTGAGAGGATCACTTGAGCCCAGGAGTTGGGGGCTGCAGTAAGCCATG
ATTGTGCCACTGCACTCCAGTCTGGGTGACAGAGCAAGACCCTGTCTCAAAAA 
 
Figure 2.4.  The sequence of PTPN22, exon 14, downloaded from 
http://www.ncbi.nlm.nih.gov. The region amplified by PCR, and the XcmI 
recognition sites are shown. The C > T transition at nucleotide 1858, shown 
in red, creates in the T allele a restriction site for XcmI. 
 
 
2.2.3.1.  Polymerase Chain Reaction (PCR) 
 
PCRs were carried out in a total volume of 25 μL.  DNAs products isolated 
from venous blood were amplified with 10 pmol of each primer, 0.2 mM of 
dNTP, 1X Taq polymerase buffer, 2.0 mM MgCl2, and 1 Unit Taq 
polymerase.  
 
In order to amplify the desired region on PTPN22 locus, 95°C 5 min initial 
denaturation step was followed by 35 cycles of 95°C for 30 sec 
(denaturation), 59°C for 30 sec (annealing), 72°C for 40 sec (extension) 
amplification step. Final extension was performed at 72°C for 5 min.  
 
PCR products were resolved on a 1.5% agarose gel by using 1X TAE. 
Ethidium bromide was added to final concentration of 30ng/ml. The 
samples were loaded onto agarose gels with 1/5 volume of loading buffer. 
The gels were run in 1X TAE at 100V for 30 minutes at room temperature. 
 
PTPN22 F 
PTPN22 R 
XcmI 
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2.2.3.2.  Restriction Enzyme Digestion 
 
The PCR amplified fragments are digested by XcmI, which recognizes the T 
allele. The sets contain PCR fragments, 1X reaction buffer and 2 Units of 
XcmI. Reaction sets were completed to a final volume of 20 μL with 
deionized water and were incubated at 37°C overnight.  Each digestion was 
resolved on 3% agarose gel by using 1X TAE. Ethidium bromide was added 
to final concentration of 30ng/ml. The samples were loaded onto agarose gel 
with 1/5 volume of loading buffer, and the fragments were visualized by 
U.V.  When the individual is homozygous for C allele, the product is 215 
bp, while the T/T homozygous individuals have the bands of 169, and 46 
bp.   
 
 
2.2.4. Statistical Analysis 
 
The results from case and control groups were compared by Fisher’s Exact 
Test. In addition, odd’s ratio value for control and case groups were 
performed in 95% confidence interval. 
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CHAPTER III 
RESULTS 
Only the samples whose alleles were adequately resolved were labeled as 
‘informative’. Extremely skewed XCI was described as the inactivation of 
one allele more than 90%. If one of the alleles was preferentially inactivated 
more than 80%, the XCI pattern was named as ‘skewed’. 
 
 
3.1. PCR-based X inactivation study of peripheral blood of Turkish 
pediatric control samples 
 
XCI was found to be informative in 155 of 211 Turkish pediatric controls 
(73.5%). Skewed XCI was observed in 11 of 155 informative controls 
(7.1%) and extremely skewed XCI was observed in only 2 of 155 control 
individuals (1.3%). Extremely skewed XCI is a very rare event in the 
healthy individuals. Our results displayed consistency with the previously 
published results (Amos-Landgraf et al., 2006). The gel image of 
representative control samples is exhibited on Figure 3.1. 
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Figure 3.1. Gel image of XCI patterns of 3 controls. Polymerase chain reaction 
products from the androgen receptor methylation assay demonstrate X 
chromosome inactivation patterns in samples P-81 (allele ratio: 75%:25%), P-82 
(85%:15%), and P-85 (67%:33%). For each sample, DNA was either undigested (-) 
or digested (+) with the methylation-sensitive restriction enzyme HpaII. Marker M; 
pUC mix, 8. 331-bp and 242- bp fragments are visible. 
 
 
3.2. PCR-based X-inactivation study of peripheral blood of Turkish 
juvenile idiopathic arthritis patients 
 
81 children diagnosed with JIA were genotyped for XCI pattern. 62 of them 
display informative XCI (76.5%). Extremely skewed XCI was observed in 8 
of the 62 informative patients (12.9%). The same pattern was observed in 
only 2 of 155 informative pediatric controls (P=0.0008; odds ratio=11.33 
(95%CI: 2.62-48.48). Skewed XCI was observed in 14 of 62 informative 
patients (22.6%) and only in 11 of 155 control group (7.1%) (P=0.0036; 
odds ratio=3.81 (95%CI: 1.65-8.83). The gel image of representative JIA 
samples is exhibited on Figure 3.2. The overall XCI pattern of JIA samples 
and control group children are summarized in Table 3.1. Skewed and 
extremely skewed pattern difference between JIA patients and control 
individuals were statistically significant. To the best of our knowledge this 
is the first study that investigates XCI pattern in the blood cells of the 
pediatric samples. 
 
        M              P-81                                       P-82            P-85                  . 
     HpaI             -               +                                 -              +              -              + 
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Figure 3.2. Gel image of XCI patterns of 3 JIA patients. Polymerase chain 
reaction products from the androgen receptor methylation assay demonstrate X 
chromosome inactivation patterns in samples 06-15 (allele ratio: not informative), 
06-16 (93%:7%), and 06-17 (51%:49%). For each sample, DNA was either 
undigested (-) or digested (+) with the methylation-sensitive restriction enzyme 
HpaII. Marker M; pUC mix, 8. 242- bp fragment is visible. 
 
 
 
Table 3.1  Proportion of the JIA patients and controls with skewed XCI 
 
Degree of skewing (%) No. (%) observed with skewing 
JIA patients  Controls 
(n=62) (n=155) 
90+    8 (12.9)*    2 (1.3) 
80-89    6 (9.7) *    9 (5.8) 
70-79    13 (21.0)    29(18.7) 
60-69    18 (29.0)    39 (25.2) 
50-59    17 (27.4)    76 (49.0) 
 
* P < 0.005 versus controls 
For comparison by Fisher’s Exact Test, For ≥80% skewing, P= 0.0036 
(odds Ratio=3.81 [95% CI 1.65-8.83]); for ≥90% skewing, P=0.0008 (odds 
ratio=11.33 [95% CI: 2.62-48.48]), 
 
                    M               06-15                    06-16                     06-17            . 
                 HpaII -             +             -             +             -            + 
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The clinical data of JIA (Table 3.2) was used in order to construct a 
correlation between skewed XCI and any clinical state of the disease. The 
only attractive correlation was established between nonrandom XCI and the 
clinical classification of JIA. It was interesting that only one patient was 
polyarticular in the group with skewed XCI pattern (7.1%) whereas 12 in 48 
patients with random XCI pattern were polyarticular (25.0%). Although the 
number of patients with skewed XCI was small, most probably skewed XCI 
may play a role more in the etiology of oligoarthritis JIA. 
 
Previously it has been reported that after years of immunosuppressive agent 
exposure, skewed XCI may occur in feline hematopoietic cells (Abkowitz et 
al. 1993). Therefore, we investigated the correlation between XCI ratios and 
the treatment of patients. At the time of sample collection, all of the patients 
were receiving some treatment. Fourteen were receiving nonsteroidal anti-
inflammatory drugs (NSAIDs), 11 were receiving methotrexate (MTX), 10 
were receiving MTX plus NSAIDs, and 9 were receiving intraarticular 
corticosteroids plus NSAIDs, while the remaining 18 were receiving various 
combinations of these and other drugs. Seven (50%) of the patients that had 
skewed XCI had received treatment with immunosuppressive agents for 6–
10 years, and 1 (7%) had received immunosuppressive treatment for 2 years. 
The remaining 6 had received antiinflammatory treatment alone. Twenty-
seven (56.3%) of the patients with random XCI had received 
immunosuppressive treatment for more than 2 years. These results indicate 
that it is unlikely that immunosuppressive therapy caused skewed XCI in the 
patients. 
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Table 3.2 Clinical characteristics and XCI status of informative JIA patients 
 Code XCI DoB 
OoD 
(y) 
Clinical 
Class 
Affected 
Joint(s) Immunosuppressive 
90+        
1 06-029 100 1996 3.5  O 3 MTX 
2 05-069 100 1990 11 O 4 NSAID;MTX 
3 05-188 95 1989 7 O 2 NSAID 
4 06-014 95 1993 14 O 2 NSAID 
5 06-013 95 1983 16 EO 8 NSAID; MTX; PRED; anti-TNF 
6 06-016 93 2002 2 O 1 NSAID;IAS 
7 06-030 92 1999 2  O 3 MTX 
8 06-008 90 1994 2 O 1 NSAID;IAS 
80-89        
9 05-179 88 2000 3  P 6 NSAID;MTX 
10 06-026 84 2001 2  O  2 MTX 
11 07-1078 83 2004 3 O 1 NSAID 
12 05-064 80 1994 7 O 3 NSAID;IAS; MTX 
13 06-020 80 2003 2 O 1 NSAID;IAS 
14 07-1080 80 2003 3 P 5 NSAID;MTX 
70-79        
15 05-170 78 1991 10 P 7 NSAID;MTX 
16 07-1087 78 1998 9 O 2 NSAID 
17 06-012 76 1986 10 O 1 NSAID 
18 05-071 75 1995 1 P 10 NSAID;MTX,PRED,Cyc 
19 05-178 75 1996 8 P 10 NSAID 
20 06-021 75 2002 2 O 1 NSAID;IAS 
21 06-052 74 2002 2.5  O 2 MTX,IAS 
22 05-187 73 1990 10 O 2 NSAID 
23 05-183 72 1999 5 O 1 NSAID;IAS 
24 06-009 71 1996 7 O 2 IAS;NSAID 
25 06-043 71 1998 2 O 2 MTX;SAZ;IAS 
26 05-065 70 1990 2 P 10 MTX;NSAID;SAZ 
27 05-063 70 1991 11 O 3 MTX;NSAID 
60-69        
28 05-070 69 1994 5 P 13 NSAID;MTX;PRED 
29 06-025 69 2000 4 O 2 NSAID,MTX,IAS 
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30 07-1079 65 1987 3 P 14 Anti-TNF,NSAID 
31 05-601 64 2001 4 O 3 NSAID 
32 05-173 63 2001 2 O 1 NSAID, 
33 05-182 63 1994 9 EO 7 NSAID;PRED;MTX 
34 06-024 62 1999 4 O 1 NSAID;PRED 
35 06-037 62 1996 4  O 3 MTX,SAZ 
36 06-044 62 1991 7 O 2 NSAID;IAS 
37 05-602 61 2003 2 O 1 NSAID 
38 06-028 61 2001 1.5  O 2 MTX 
39 05-073 60 1995 4 P 7 NSAID;IAS 
40 05-072 60 1988 1 P 10 NSAID;MTX 
41 05-062 60 1984 11 O 3 MTX;NSAID 
42 06-051 60 2000 3  O 2 MTX 
43 05-066 60 1998 3  O 1 NSAID 
44 07-1084 60 1998 9 O 1 NSAID 
45 07-1086 60 1995 10 O 2 NSAID 
50-59        
46 05-168 58 1990 9 P 9 NSAID;MTX;anti-TNF;PRED 
47 06-034 57 1999 3  O 2 MTX 
48 05-167 56 2002 9 EO 8 NSAID;MTX;PRED 
49 05-169 56 1987 4 P 6 NSAID;MTX 
50 06-038 56 1998 3  O 2 MTX 
51 05-177 55 1992 10 P 5 NSAID;MTX 
52 06-019 54 2000 4 O 1 NSAID;IAS 
53 06-027 53 1999 7 O 2 MTX;NSAID 
54 06-031 53 2000 2  O 2 MTX 
55 06-048 52 2002 1  O 2 MTX 
56 05-166 51 1980 13 P 12 MTX, PRED,SAZ, Leflunomid 
57 05-185 51 1998 6 O 2 NSAID;MTX;PRED; 
58 06-046 51 2005 1.5  O 2 MTX 
59 06-045 50 2002 2  O 2 MTX 
60 06-053 50 1998 2 O 1 SAZ 
61 07-1081 50 2002 5 O 2 NSAID 
62 07-1085 50 1998 9 O 1 NSAID,SAZ 
DoB: Date of birth, OoD: Onset of disease, y: year, O: oligoarticular, P: polyarticular, EO: 
extended oligoarticular, Anti-TNF: Tumor necrosis factor antagonist , MTX: methotrexate, 
NSAID: non-steroidal anti-inflammatory drugs, PRED: prednisolone, IAS: intraarticular 
corticosteroids, SAZ: sulfasalazine. 
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3.3. PCR-based X-inactivation study of peripheral blood of French 
control samples 
 
Among 100 French controls, 69 were informative at AR locus. This number 
represents 69.0% of the control population. 12 of 69 informative control 
cases displayed skewed XCI (17.4%). Only 2 of 69 informative control 
women display extremely skewed XCI pattern (2.9%). The gel image of 
representative control samples is exhibited on Figure 3.3. 
 
 
 
 
Figure 3.3. Gel image of XCI patterns of 3 controls. Polymerase chain reaction 
products from the androgen receptor methylation assay demonstrate X 
chromosome inactivation patterns in samples NRL33 (allele ratio: 90%:10%), 
NRL34 (not informative), and NRL36 (50%:50%). For each sample, DNA was 
either undigested (-) or digested (+) with the methylation-sensitive restriction 
enzyme HpaII. Marker M; pUC mix, 8. 331-bp and 242- bp fragments are visible. 
 
 
3.4. PCR-based X-inactivation study of peripheral blood of French 
rheumatoid arthritis patients   
 
Informative XCI pattern was observed in 54 of 86 French RA patients 
(62.8%). Extremely skewed XCI was observed in 10 of 54 informative 
patients (18.5%). The same pattern was observed in 2 of 69 informative 
French controls (2.9) (P=0.005, odds ratio=7.6 with 95%CI between 1.59 
and 36.42). Skewed XCI was present in 17 of 54 informative patients 
(31.5%) while in 12 of 69 informative controls (17.4%) (P=1.00; OR: 0.9, 
     M                 NRL33                          NRL34                         NRL36         . 
   HpaII          -             +             -           +            -            + 
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95%CI=0.3-2.5). The results were significant for extremely skewed XCI, 
but not for skewed XCI. The overall XCI pattern of RA samples and control 
group are summarized in Table 3.3. Representative gel image of XCI pattern 
of French RA patients was displayed in Figure 3.4. The XCI patterns for all 
of French RA patients are listed in Table 3.4. 
 
 
 
 
 
Figure 3.4. Gel image of XCI patterns of 4 RA patients. Polymerase chain reaction 
products from the androgen receptor methylation assay demonstrate X 
chromosome inactivation patterns in samples PR48 (allele ratio: 90%:10%), PR51 
(80%:20%), PR52 (50%:50%), and PR54 (60%:40%). For each sample, DNA was 
either undigested (-) or digested (+) with the methylation-sensitive restriction 
enzyme HpaII. Marker M; pUC mix, 8. 242- bp fragment is visible. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   M                  PR48                         PR51                         PR52                      PR54          . 
  HpaII             -             +                -             +               -              +              -               + 
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Table 3.3  Proportion of the French RA patients and controls with skewed 
XCI 
 
Degree of skewing (%) No. (%) observed with skewing 
RA patients  Controls 
(n=54) (n=69) 
90+    10 (18.5)*    2 (2.9) 
80-89    7 (13.0)    10 (14.5) 
70-79    9 (16.7)    10 (14.5) 
60-69    9 (16.7)    12 (17.4) 
50-59    19 (35.2)    35 (50.7) 
 
* P< 0.05 versus controls 
For comparison by Fisher’s Exact Test, For ≥80% skewing, P= 1.00 (odds 
Ratio=0.9 [95% CI 0.3–2.5]); for ≥90% skewing, P=0.005 (odds ratio=7.6 
[95% CI 1.59–36.42]), 
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Table 3.4. XCI patterns of French RA patients. 
 
   Code  XCI 
90+ 10/54 (18,5%)    
1 1  PR 1  90 
2 2  PR 19  90 
3 3  PR 48  90 
4 4  PR 64  90 
5 5  PR 76  90 
6 6  PR 165  90 
7 7  PR 179  90 
8 8  PR 184  90 
9 9  PR 188  90 
10 10  PR 211  90 
80-89 7/54(13,0%)    
11 1  PR 134  85 
12 2  PR 177  85 
13 3  PR 194  85 
14 4  PR 2  80 
15 5  PR 3  80 
16 6  PR 51  80 
17 7  PR 136  80 
70-79 9/54(16,7%)    
18 1  PR 13  75 
19 2  PR 158  75 
20 3  PR 197  75 
21 4  PR 10  70 
22 5  PR 40  70 
23 6  PR 71  70 
24 7  PR 185  70 
25 8  PR 161  70 
26 9  PR 202  70 
60-69 9/54(16,7%)    
27 1  PR 37  65 
28 2  PR 5  60 
29 3  PR 54  60 
30 4  PR 58  60 
31 5  PR 160  60 
32 6  PR 172  60 
33 7  PR 190  60 
34 8  PR 195  60 
35 9  PR 200  60 
50-59 19/54(35,2%)    
36 1  PR 79  55 
37 2  PR 82  55 
38 3  PR 141  55 
39 4  PR 155  55 
40 5  PR 159  55 
41 6  PR 52  50 
42 7  PR 62  50 
43 8  PR 63  50 
44 9  PR 66  50 
45 10  PR 92  50 
46 11  PR 105  50 
47 12  PR 145  50 
48 13  PR 154  50 
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49 14  PR 169  50 
50 15  PR 170  50 
51 16  PR 193  50 
52 17  PR 198  50 
53 18  PR 205  50 
54 19  PR 212  50 
Not inform.  30/84(35,7%)    
55 1  PR 20  NI 
56 2  PR 21  NI 
57 3  PR 24  NI 
58 4  PR 31  NI 
59 5  PR 47  NI 
60 6  PR 59  NI 
61 7  PR 60  NI 
62 8  PR 65  NI 
63 9  PR 77  NI 
64 10  PR 78  NI 
65 11  PR 85  NI 
66 12  PR 88  NI 
67 13  PR 93  NI 
68 14  PR 110  NI 
69 15  PR 131  NI 
70 16  PR 135  NI 
71 17  PR 138  NI 
72 18  PR 139  NI 
73 19  PR 146  NI 
74 20  PR 149  NI 
75 21  PR 151  NI 
76 22  PR 164  NI 
77 23  PR 167  NI 
78 24  PR 187  NI 
79 25  PR 191  NI 
80 26  PR 192  NI 
81 27  PR 203  NI 
82 28  PR 206  NI 
83 29  PR 209  NI 
84 30  PR 213  NI 
Not Worked     
85 1  PR 148  
86 2  PR 162  
XCI: X chromosome inactivation pattern 
 
 
 
3.5.  Determination of frequency of PTPN22 genotypes in Turkish 
control samples 
 
As SNP frequencies may vary across populations, we investigated the 
PTPN22 polymorphism in 68 Turkish healthy unrelated individuals.  The 
risk allele, T, was found to be present in 8 of 136 chromosomes (5.9%): 6 
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C/T and 1 T/T.  The genotypes were also confirmed by high-density 
microarray analysis (Appendix J). 
 
 
3.6.  Determination of frequency of PTPN22 genotypes in Turkish 
systemic sclerosis patients 
 
71 individuals diagnosed with SSc were genotyped for PTPN22 C1858T 
SNP.  4.2% of individuals with SSc were heterozygous with respect to 
1858T, compared with 8.8% of the healthy controls, and none of individuals 
with SSc were homozygous with respect to 1858T, compared with 1.4% of 
the healthy controls. The 1858T allele frequency was 2.11% compared to 
5.88% in controls. These results suggest that the PTPN22 allele 1858T is 
not associated with SSc in Turkish population. The overall genotype 
frequencies of PTPN22 are summarized in Table 3.5. The genotypes were 
also confirmed by high-density microarray analysis (Appendix J). 
 
 
Table 3.5  Frequency of PTPN22 genotypes in individuals with SSc and 
controls 
                                  No. (frequency) of PTPN22 genotype  
                                  Controls                    SSc 
Genotypes                  (n=68)                     (n=71) 
 
C/C                           61 (89.7%)                68 (95.8%) 
C/T                           6 (8.8%)                    3 (4.2%) 
T/T                           1 (1.5%)                    0 (0%) 
T allele frequency     8/136 (5.88%)          3/142 (2.11%) 
P=0.13, OR: 0.34 (95% CI: 0.089-1.33) 
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3.7.  Determination of frequency of PTPN22 genotypes in Turkish 
autoimmune thyroid disease patients 
 
104 individuals diagnosed with AITD were genotyped for PTPN22 C1858T 
SNP.  7 (6.7%) of individuals with AITD were heterozygous with respect to 
1858T, compared with 8.8% of the healthy controls, and one (0.96%) of 
individuals with AITD was homozygous with respect to 1858T, compared 
with 1.4% of the healthy controls. The 1858T allele frequency was 4.33% 
compared to 5.88% in controls. These results suggest that the PTPN22 allele 
1858T is not associated with AITD in Turkish population. The overall 
genotype frequencies of PTPN22 are summarized in Table 3.6. The 
genotypes were also confirmed by high-density microarray analysis 
(Appendix J). 
 
 
Table 3.6  Frequency of PTPN22 genotypes in individuals with AITD and 
controls 
                                  No. (frequency) of PTPN22 genotype  
                                  Controls                    AITD 
Genotypes                  (n=68)                     (n=104) 
 
C/C                           61 (89.7%)                96 (92.3%) 
C/T                           6 (8.8%)                    7 (6.7%) 
T/T                           1 (1.5%)                    1 (0.96%) 
T allele frequency     8/136 (5.88%)          9/208 (4.33%) 
P=0.61, OR: 0.72 (95% CI: 0.27-1.92) 
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3.8.  High-density microarray analysis 
 
In order to test the hypothesis that disturbances in XCI may cause female 
predominance in autoimmune disorders, we developed a research strategy in 
which we conducted a comprehensive genomic study by using high-density 
microarray analysis. For the custom made microarray, all known 
nonsynonymous, synonymous and intronic SNPs on X chromosome were 
listed using NCBI and Ensembl databases. Redundant and nonappropriate 
SNPs were eliminated.  In the end, 1618 nonsynonymous, 1091 
synonymous, and 2802 intronic SNPs on X chromosome were included on 
the array. 166 SNPs from other autosomal chromosomes that are known to 
be associated with several autoimmune disorders were added. The exonic 
SNPs cover 783 genes and the intronic SNPs correspond to 160 genes. 56 
SSc, 82 AITDs, 48 PEE, 20 JIA, 2 SICCA, 7 pediatric SSc, and 250 control 
samples (total 465 samples) were used in this study. 
 
After the analysis of the data, the candidate alleles, which have OR>1.0 and 
p<0.05, were found for JIA (Table 3.7).  
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Table 3.7. JIA Allelic Association Results (OR>1.0, p<0.05) 
 
Chr SNP A1 Aff UnAff A2 X2 P OR L 95 c.i. U 95% c.i.
23 rs15943 G 0.08 0.01 C 11.23 0.0008 8.35 1.92 9.56
23 rs2235708 A 0.06 0.01 G 5.74 0.0166 6.09 1.14 9.23
23 rs6324 T 0.05 0.01 C 4.91 0.0267 5.43 1.02 5.88
23 rs1123773 A 0.05 0.01 G 4.55 0.0329 5.15 0.97 5.83
23 rs5030868 T 0.05 0.01 C 4.52 0.0335 5.13 0.96 36.38
23 rs1199470 G 0.08 0.02 A 6.34 0.0118 4.93 1.25 5.30
23 rs7063566 T 0.10 0.02 G 8.19 0.0042 4.88 1.48 8.52
23 rs6624109 G 0.08 0.02 T 5.36 0.0206 4.33 1.13 6.27
23 rs12395804 T 0.23 0.06 C 13.4 0.0003 4.19 1.84 6.09
23 rs17327496 G 0.23 0.07 C 12.78 0.0004 4.06 1.78 6.09
23 rs6653146 G 0.08 0.02 A 4.54 0.0331 3.86 1.02 0.69
23 rs1414368 A 0.08 0.02 G 4.39 0.0361 3.75 1.00 5.90
23 rs7050548 C 0.22 0.07 G 9.76 0.0018 3.62 1.54 0.73
23 rs16990617 T 0.08 0.02 C 4.03 0.0447 3.56 0.95 7.41
23 rs5964770 A 0.08 0.02 G 4.03 0.0447 3.56 0.95 0.75
23 rs6524876 T 0.08 0.02 A 4.03 0.0447 3.56 0.95 0.75
23 rs12006627 C 0.08 0.02 A 4.03 0.0447 3.56 0.95 16.09
23 rs12012307 G 0.20 0.07 A 7.91 0.0049 3.18 1.37 0.78
23 rs12836780 C 0.55 0.29 A 12.21 0.0005 3.06 1.59 4.49
23 rs12009120 T 0.30 0.12 G 9.68 0.0019 3.03 1.46 0.81
23 rs331369 T 0.58 0.31 G 11.86 0.0006 3.03 1.57 0.82
23 rs217994 A 0.73 0.47 G 9.66 0.0019 2.98 1.46 4.33
23 rs217992 G 0.73 0.47 C 9.66 0.0019 2.98 1.46 19.35
23 rs17281349 A 0.13 0.05 G 4.58 0.0323 2.93 1.05 4.62
23 rs9697983 G 0.13 0.05 T 4.54 0.0331 2.91 1.04 4.97
23 rs5955897 C 0.32 0.14 A 8.48 0.0036 2.84 1.37 0.84
23 rs5939385 T 0.48 0.25 C 9.9 0.0017 2.76 1.44 4.46
23 rs1202985 T 0.18 0.08 C 4.86 0.0276 2.61 1.08 0.84
23 rs17311504 A 0.15 0.06 C 4.07 0.0438 2.55 1.00 0.86
23 rs5982867 A 0.18 0.08 G 4.4 0.0359 2.50 1.04 0.91
23 rs5955838 T 0.18 0.08 A 4.29 0.0383 2.46 1.02 0.86
23 rs5955593 C 0.30 0.15 T 6.11 0.0135 2.42 1.18 4.84
23 rs7052290 A 0.28 0.14 G 5.47 0.0193 2.37 1.13 32.61
23 rs7051930 G 0.30 0.15 A 5.74 0.0166 2.36 1.15 4.15
23 rs1016625 A 0.50 0.30 C 6.96 0.0084 2.35 1.23 4.52
23 rs1091269 T 0.68 0.47 C 6.13 0.0133 2.33 1.17 4.96
23 rs6524628 A 0.65 0.45 G 5.99 0.0144 2.28 1.16 nan
23 rs12688102 G 0.53 0.33 C 6.38 0.0115 2.27 1.18 16.69
23 rs6617216 T 0.66 0.46 A 5.57 0.0183 2.26 1.13 4.25
23 rs7885068 A 0.28 0.15 T 4.71 0.0300 2.22 1.06 4.25
23 rs5955882 T 0.24 0.12 C 3.97 0.0464 2.20 1.00 4.03
23 rs5923521 T 0.65 0.46 G 5.28 0.0216 2.17 1.11 4.18
23 rs6524627 A 0.65 0.46 T 5.27 0.0217 2.17 1.11 4.08
23 rs5987015 G 0.48 0.29 A 5.64 0.0176 2.17 1.13 4.21
23 rs1988916 G 0.66 0.47 C 4.9 0.0268 2.16 1.08 4.07
23 rs5927083 C 0.28 0.15 T 4.33 0.0374 2.15 1.03 0.91
23 rs6623640 T 0.65 0.46 C 5.16 0.0232 2.15 1.10 4.05
23 rs5986916 C 0.55 0.37 T 5.26 0.0218 2.15 1.10 4.05
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* Chromosome 23 denotes the X-chromosome 
 
 
 
 
 
Chr SNP A1 Aff UnAff A2 X2 P OR L 95 c.i. U 95% c.i.
23 rs2520324 A 0.60 0.42 G 5.17 0.0230 2.12 1.10 3.97
23 rs2192371 G 0.53 0.34 A 5.27 0.0217 2.11 1.10 4.03
23 rs2078865 A 0.60 0.42 G 5.11 0.0238 2.11 1.09 28.99
23 rs2464544 T 0.60 0.42 G 5.05 0.0246 2.10 1.09 0.93
23 rs2238928 T 0.60 0.42 C 5.05 0.0246 2.10 1.09 4.31
23 rs2704831 T 0.60 0.42 C 4.97 0.0258 2.09 1.08 6.30
23 rs723119 G 0.48 0.30 A 5.02 0.0250 2.08 1.08 3.99
23 rs2854426 C 0.60 0.42 G 4.84 0.0278 2.07 1.07 0.94
23 rs5936218 G 0.63 0.45 T 4.7 0.0302 2.06 1.06 0.94
23 rs7051365 T 0.43 0.27 C 4.72 0.0299 2.05 1.06 3.96
23 rs5952296 T 0.30 0.17 C 3.92 0.0479 2.03 0.99 4.65
23 rs5935984 C 0.43 0.27 T 4.58 0.0324 2.03 1.05 0.94
23 rs5930931 A 0.63 0.45 C 4.38 0.0364 2.01 1.03 4.00
23 rs5975721 T 0.63 0.45 C 4.38 0.0364 2.01 1.03 3.91
23 rs5975720 A 0.63 0.45 T 4.38 0.0364 2.01 1.03 0.94
23 rs4829829 G 0.63 0.45 A 4.38 0.0364 2.01 1.03 0.95
23 rs5977755 G 0.63 0.45 C 4.38 0.0364 2.01 1.03 8.16
23 rs723556 C 0.60 0.43 T 4.38 0.0364 2.00 1.03 0.95
23 rs12847225 C 0.50 0.33 A 4.5 0.0338 1.99 1.04 0.95
23 rs2181307 A 0.63 0.46 G 4.28 0.0386 1.99 1.03 0.95
23 rs1152198 T 0.43 0.27 A 4.31 0.0378 1.99 1.03 0.95
23 rs5973488 A 0.55 0.38 G 4.23 0.0398 1.96 1.02 0.95
23 rs2428147 A 0.58 0.41 G 3.93 0.0475 1.95 1.00 1.11
23 rs1410962 G 0.55 0.39 A 4.14 0.0418 1.94 1.02 27.42
23 rs1410961 C 0.55 0.39 T 4.14 0.0418 1.94 1.02 0.95
23 rs4829392 C 0.55 0.39 T 4.14 0.0418 1.94 1.02 8.13
23 rs12852223 G 0.55 0.39 A 3.89 0.0485 1.93 0.99 27.31
23 rs4492499 A 0.55 0.39 G 3.89 0.0485 1.93 0.99 14.63
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CHAPTER IV 
DISCUSSION 
Our immune system can react to any foreign structure with the help of 
receptors on the surface of B and T cells, while it is tolerant to its own self 
antigens. The immune system mediates self tolerance by killing self-reactive 
lymphocytes by apoptosis, or by silencing them by the anergy mechanism 
(Goodnow et al., 2005). When self antigens escape from these mechanisms, 
autoimmune disorders develop. Although how these molecules escape from 
tolerance are not entirely known, a combination of genetic variants, 
environmental factors like pathogen exposure, pregnancy, smoking and diet 
are thought to have a role in the etiology of autoimmune diseases.   
 
A female predominance is the characteristic of the most autoimmune 
diseases (Whitacre, 2001). For several years candidate mechanisms that 
could be important in pathogenesis of autoimmunity have been uncovered. 
The main differences between males and females are hormonal status, 
pregnancy and sex chromosomes. Hormones are good candidates for the 
female predominance in autoimmune disorders. However they fail to 
explain the pediatric type of autoimmune disorders in the children before 
puberty. Another possible mechanism could be the pregnancy related 
microchimerism. Although there are studies that show association of 
microchimerism and scleroderma (Artlett et al., 1998; Nelson et al., 1998), 
these reports cannot explain why women with no history of pregnancy and 
children are subject to autoimmune disorders. Third difference is sex 
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chromosomes. Females have two X chromosomes, and for dosage 
compensation, one of them is randomly inactivated (Lyon, 1961), therefore, 
females are mosaic. It was reported that disturbances in the XCI pattern may 
result in inadequate X-linked antigen representation in the thymus (Stewart, 
1998).  
 
In this study, our goal was to investigate the role of XCI in the pathogenesis 
of autoimmune disorders that show female predominance. RA is an 
autoimmune disease with unknown cause. JIA is the pediatric form of the 
RA. We have chosen JIA also to exclude the possible reasons of 
microchimerism and hormones, as the disease onset is before puberty. In 
this study, JIA patients and children controls form Turkish population, and 
RA patients and controls from French population were investigated. We 
have chosen polyarticular and oligoarticular subtypes of JIA as they have 
female predominance.  
 
We demonstrated skewed XCI patterns (>80:20) in peripheral blood 
mononuclear cells of a significant proportion (22.6%) of females with JIA 
in Turkish (OR: 3.81(95%CI: 1.65-8.83); P=0.0036), and RA (31.5%) in 
French populations (OR:0.9 (95%CI:0.3-2.5); P=1.00). The effect is more 
pronounced for patterns of extremely skewed XCI in the Turkish JIA 
[12.9%, OR: 11.33 (95% CI 2.62-48.48); P=0.0008] and the French RA 
[18.5%, OR: 7.6 (95% CI 1.59-36.42); P=0.005] patients. In Turkish female 
pediatric controls 7.1% demonstrate skewed and 1.3% demonstrate 
extremely skewed XCI. In French controls 17.4% demonstrate skewed and 
2.9% demonstrate extremely skewed XCI. These ratios are in accordance 
with the XCI profiles of other diverse control populations from US (Chitnis 
et al. 2000, Amos-Landgraf et al. 2006).  
 
It has been reported that after several years of immunosuppressive 
treatment, skewed XCI may occur (Abkowitz et al. 1993). Therefore, we 
investigated whether the treatments of the patients play a role on the XCI 
ratios. Along with previous observations (Ozbalkan et al., 2005; Ozcelik et 
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al., 2006), our results do not indicate that immunosuppressive treatment 
cause skewed XCI. 
 
There are several mechanisms that are used in order to determine XCI 
pattern, such as protein isoforms and transcription based methods.  A variety 
of genes are used to determine XCI status including G6PD (Prchal and 
Guan, 1993), IDS (iduronate-2-sulfatase) (Gregg et al., 2000; el-Kassar et 
al., 1997), MPP1 (also known as p55) (Luhovy et al., 1995), BTK (Bruton 
tyrosine kinase), and FHL-1 (4.5 LIM domain 1) (Liu et al., 2003). In this 
study we used X chromosome inactivation assay, which is based on DNA 
methylation and tandem CAG repeats. This assay is more widely used 
because of the variable number of CAG nucleotide repeats, which are 
informative in most of the patients.  In our study we had a limited number of 
patients, as we used only specific subtypes that have female predominance. 
Therefore, it is important to have most of the patients informative for the 
assay.  
 
Our results suggest that a significant proportion of juvenile idiopathic 
arthritis and rheumatoid arthritis patients have extremely skewed XCI.  
There are mainly two reasons for skewed XCI: primary and secondary. 
Primary cause, which results from a mutation in XIST (X-inactive- specific 
transcript) and Xic, is very rare (Plenge et al., 1997; Puck, 1998). The 
secondary causes are deleterious X-linked mutations, X-chromosome 
rearrangements, aging, twinning, or monoclonal expansion of cells (Brown, 
1999). Based on observations that skewed XCI cosegregates with the 
disease and recurrent spontaneous abortions are elevated in skewed group 
(Ozcelik et al., 2006), we propose that as a secondary cause, a putative 
lethal mutation on the X-chromosome may result in a cell-survival 
disadvantage.  Cells that carry a putative lethal mutation in their active X do 
not survive because of the mutation, causing loss of mosaicism. The self 
antigens on the inactive X of these cells are not presented in the thymus or 
in other peripheral sites. Because of an unknown mechanism, at a later stage 
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of the life, these self antigens encounter the lymphocytes. Therefore, these 
self antigens are recognized as non-self and cause autoimmunity.  
 
In order to determine whether skewed XCI is specific to blood or observed 
in other tissues as well, previously in our group buccal mucosa, hair and 
affected tissues were collected for the patients that have skewed XCI. In 
both AITD and PEE patients, skewed XCI was shown in buccal cells 
(ectodermal origin) of the patients that have skewed XCI in their blood 
(measodermal origin) (Ozcelik et al., 2006; Uz et al., 2007). As the degree 
of skewing is at the extreme profiles (>95%) in most patients, we believe 
that the self antigens escape from presentation because of skewing. If the 
skewing was not the cause but the result of the autoimmune disease, we 
would observe more patients in the milder ranges (80:20 or 90:10). 
 
Another evidence for our hypothesis is the maternally inherited skewed XCI 
cosegregates with the disease in AITD patients (Ozcelik et al., 2006). We 
also showed that recurrent spontaneous abortions increase in the skewed 
group (Ozcelik et al., 2006; Bagislar et al., 2006; Uz et al., 2007). Lethal X-
linked mutation can be compatible in females because of the XCI, while is 
lethal in hemizygous males.  
      
Although extremely skewed XCI is rare in general population, the ratio 
increases as the age increases (Sangha et al. 1999). Previously in our group, 
it was shown that the age alone is unlikely to cause skewed XCI in AITD 
patients (Ozcelik et al., 2006). Here we again show that the age of the 
patients do not play a significant role in skewed XCI as there is extremely 
skewed XCI in a significant proportion of JIA patients, which is the 
pediatric form of RA.  
 
Autoimmune disorders are complex diseases with unknown causes. Several 
genes, such as PTPN22, are shown to be associated with several diseases. 
The frequency of the C1858T SNP of PTPN22 changes in different 
populations, therefore we investigated the frequency of the PTPN22 
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genotype in Turkish population.  For this purpose 104 AITD, 71 SSc 
patients and 68 unrelated healthy individuals were included.  Unlike in 
North American and European populations, we did not observe an 
association between C1858T SNP and AITD and SSc in Turkish population. 
The T allele frequency is 2.11% in SSc, and 4.33% in AITD compared to 
5.88% in controls. It was also shown in Japanese population that this SNP 
was not associated with AITD (Ban et al., 2005).  Later on, it was shown 
that another SNP on PTPN22 promoter (1123G>C) was associated with 
T1D in Japanese and Korean populations (Kawasaki et al., 2006). It might 
also be the case for the Turkish population. Therefore, other SNPs on 
PTPN22 must be investigated. 
 
In this study we also investigated which X-linked genes which might be 
associated with skewed XCI.  Therefore, we conducted a comprehensive 
genomic study by using high-density microarray analysis.  After elimination 
of redundant and nonappropriate SNPs from NCBI and Ensembl databases, 
1618 nonsynonymous, 1091 synonymous, and 2802 intronic SNPs on X 
chromosome were included on the array. In addition, 166 SNPs from other 
autosomal chromosomes that are known to have association with certain 
autoimmune diseases were added. The exonic SNPs cover 783 genes and 
the intronic SNPs correspond to 160 genes. After the analysis of the data we 
identified the following SNPs to be associated with JIA: PDHA1, MCF2, 
MAOB, SRPX, and G6PD (OR>1.0 and p<0.05; please see Table 3.7 for a 
complete list).  
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Future Perspectives  
 
In summary, there is a female predominance in the majority of the 
autoimmune diseases. We showed that skewed XCI is associated with 
autoimmune diseases including JIA and RA. We hypothesized that a 
putative X-linked lethal mutation may result in a cell-survival disadvantage 
causing skewed XCI. In order to find the culprit X-linked genes that might 
be associated with skewed XCI, we conducted a custom made X-linked 
SNP study. We examined the X-linked SNP mapping and disease 
association and determined the SNPs that have association with JIA with 
OR>1.0 and p<0.05. As a future perspective, in order to validate our 
findings, we plan to conduct a replication study by selecting the 
significantly correlating SNPs in additional case-control series. The strongly 
associated coding SNPs would suggest that corresponding genes would be 
further studied to understand their role in the pathogenesis of JIA.  First, the 
genes’ association with immune system should be studied. The proteins, 
which are encoded by these genes, should also be searched whether they 
interact with other proteins that play role in the immune sytem. According 
to the findings, fuctional analysis can be done. 
 
In this study, we selected common X-linked SNPs with 0.4-0.5 
heterozygosity rate in order to find diseases association. With the discovery 
of novel high-throughput sequencing techniques, called next generation 
sequencing, X-linked lethal mutations can be directly identified. By using 
targeted sequencing approaches, the coding regions in the X chromosome, 
which constitute a total of 1.47 Mb, can be completely sequenced and 
functional variations can be evaluated whether they have a lethal effect.  
This high-throughput technique would be cost-effective and powerful 
compared to Sanger sequencing. This technique also would be advantageous 
with respect to identification of the variants by using less number of patients 
in a short period of time. 
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APPENDICIES 
 
Appendix A. The list of the healthy Turkish children and their XCI pattern 
Number Sample XCI Pattern 
90+ n=2/155(1.3%) 
  1 1 05-332 100 
2 2 06-072 100 
80-89 n=9/155(5.8%) 
  3 1 05-583 88 
4 2 09-006 87 
5 3 05-370 85 
6 4 05-369 85 
7 5 09-056 85 
8 6 06-056 85 
9 7 06-071 82 
10 8 05-588 82 
11 9 09-023 80 
70-79 n=29/155(18.7%) 
  12 1 06-057 79 
13 2 06-070 78 
14 3 09-027 77 
15 4 09-079 75 
16 5 09-111 75 
17 6 05-595 75 
18 7 06-077 75 
66 
 
19 8 05-587 75 
20 9 05-348 75 
21 10 05-359 75 
22 11 05-599 75 
23 12 06-068 75 
24 13 09-106 75 
25 14 09-109 75 
26 15 09-014 75 
27 16 09-009 75 
28 17 09-038 74 
29 18 05-375 73 
30 19 05-372 73 
31 20 06-066 73 
32 21 05-342 72 
33 22 09-045 71 
34 23 06-059 70 
35 24 05-354 70 
36 25 06-069 70 
37 26 09-067 70 
38 27 09-073 70 
39 28 09-110 70 
40 29 09-091 70 
60-69 n=39/155(25.2%) 
  41 1 05-347 68 
42 2 09-031 68 
43 3 05-331 67 
44 4 05-585 66 
45 5 05-360 65 
46 6 09-058 65 
47 7 05-592 65 
48 8 09-047 65 
49 9 09-008 65 
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50 10 09-010 65 
51 11 09-049 65 
52 12 09-080 65 
53 13 09-043 65 
54 14 09-026 65 
55 15 09-100 65 
56 16 05-357 64 
57 17 05-366 64 
58 18 05-364 63 
59 19 05-596 63 
60 20 05-356 62 
61 21 05-581 62 
62 22 06-074 62 
63 23 06-081 62 
64 24 05-350 61 
65 25 05-374 61 
66 26 05-377 61 
67 27 06-075 61 
68 28 09-018 61 
69 29 09-017 60 
70 30 06-061 60 
71 31 05-591 60 
72 32 05-339 60 
73 33 09-048 60 
74 34 09-050 60 
75 35 09-084 60 
76 36 09-101 60 
77 37 09-114 60 
78 38 09-095 60 
79 39 09-042 60 
50-59 n=76/155(49.0%) 
  80 1 05-341 58 
68 
 
81 2 05-358 58 
82 3 05-367 58 
83 4 05-582 58 
84 5 05-594 58 
85 6 06-058 58 
86 7 05-333 57 
87 8 05-351 57 
88 9 05-346 57 
89 10 06-078 56 
90 11 06-060 55 
91 12 05-337 55 
92 13 05-355 55 
93 14 05-368 55 
94 15 05-586 55 
95 16 05-338 55 
96 17 05-336 55 
97 18 06-067 55 
98 19 09-003 55 
99 20 09-015 55 
100 21 09-002 55 
101 22 09-036 55 
102 23 09-032 55 
103 24 09-052 55 
104 25 09-055 55 
105 26 09-062 55 
106 27 09-064 55 
107 28 09-065 55 
108 29 09-068 55 
109 30 09-070 55 
110 31 09-085 55 
111 32 09-087 55 
112 33 09-093 55 
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113 34 09-096 55 
114 35 09-102 55 
115 36 09-105 55 
116 37 09-108 55 
117 38 09-115 55 
118 39 09-117 55 
119 40 09-120 55 
120 41 09-022 55 
121 42 05-349 54 
122 43 05-584 54 
123 44 05-329 53 
124 45 05-593 53 
125 46 09-034 53 
126 47 09-024 53 
127 48 09-028 52 
128 49 09-005 51 
129 50 09-037 51 
130 51 05-363 51 
131 52 06-080 51 
132 53 05-590 50 
133 54 05-343 50 
134 55 05-598 50 
135 56 06-079 50 
136 57 09-030 50 
137 58 09-016 50 
138 59 09-035 50 
139 60 09-007 50 
140 61 09-041 50 
141 62 09-051 50 
142 63 09-060 50 
143 64 09-061 50 
144 65 09-066 50 
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145 66 09-072 50 
146 67 09-075 50 
147 68 09-086 50 
148 69 09-088 50 
149 70 09-089 50 
150 71 09-094 50 
151 72 09-097 50 
152 73 09-099 50 
153 74 09-112 50 
154 75 09-113 50 
155 76 09-119 50 
NI n=56/211(26.5%) 
  156 1 05-330 NI 
157 2 05-344 NI 
158 3 05-345 NI 
159 4 05-361 NI 
160 5 05-362 NI 
161 6 05-365 NI 
162 7 05-371 NI 
163 8 05-373 NI 
164 9 05-376 NI 
165 10 05-379 NI 
166 11 05-589 NI 
167 12 05-600 NI 
168 13 06-055 NI 
169 14 06-062 NI 
170 15 06-065 NI 
171 16 06-073 NI 
172 17 06-076 NI 
173 18 05-353 NI 
174 19 05-378 NI 
175 20 05-352 NI 
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176 21 09-046 NI 
177 22 09-004 NI 
178 23 09-013 NI 
179 24 09-040 NI 
180 25 09-039 NI 
181 26 09-044 NI 
182 27 09-020 NI 
183 28 09-025 NI 
184 29 09-029 NI 
185 30 09-021 NI 
186 31 09-019 NI 
187 32 09-012 NI 
188 33 09-033 NI 
189 34 09-011 NI 
190 35 09-053 NI 
191 36 09-054 NI 
192 37 09-057 NI 
193 38 09-059 NI 
194 39 09-063 NI 
195 40 09-069 NI 
196 41 09-071 NI 
197 42 09-074 NI 
198 43 09-076 NI 
199 44 09-077 NI 
200 45 09-078 NI 
201 46 09-081 NI 
202 47 09-082 NI 
203 48 09-083 NI 
204 49 09-090 NI 
205 50 09-092 NI 
206 51 09-098 NI 
207 52 09-103 NI 
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208 53 09-104 NI 
209 54 09-107 NI 
210 55 09-116 NI 
211 56 09-118 NI 
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Appendix B. The list of French controls and their XCI pattern 
Number Sample XCI Pattern 
90+ 2/69(2.9%)   
1 1 NRL 33 90 
2 2 NRL 110 90 
80-89 10/69 (14.5%)  
3 1 NRL 76 85 
4 2 NRL 77 85 
5 3 NRL 121 85 
6 4 NRL 46 80 
7 5 NRL 7 80 
8 6 NRL 24 80 
9 7 NRL 30 80 
10 8 NRL 28 80 
11 9 NRL 22 80 
12 10 NRL 125 80 
70-79 10/69 (14.5%)  
13 1 NRL 40 75 
14 2 NRL 41 75 
15 3 NRL 105 75 
16 4 NRL 124 75 
17 5 NRL 126 75 
18 6 NRL 56 70 
19 7 NRL 72 70 
20 8 NRL 83 70 
21 9 NRL 85 70 
22 10 NRL 122 70 
60-69 12/69 (17.4%)  
23 1 NRL 66 65 
24 2 NRL 9 60 
25 3 NRL 29 60 
26 4 NRL 37 60 
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27 5 NRL 58 60 
28 6 NRL 68 60 
29 7 NRL 73 60 
30 8 NRL 84 60 
31 9 NRL 100 60 
32 10 NRL 101 60 
33 11 NRL 107 60 
34 12 NRL 123 60 
50-59 35/69(50.7%)  
35 1 NRL 10 55 
36 2 NRL 25 55 
37 3 NRL 27 55 
38 4 NRL 31 55 
39 5 NRL 57 55 
40 6 NRL 95 55 
41 7 NRL 97 55 
42 8 NRL 103 55 
43 9 NRL 115 55 
44 10 NRL 130 55 
45 11 NRL 135 55 
46 12 NRL 136 55 
47 13 NRL 139 55 
48 14 NRL 4 50 
49 15 NRL 13 50 
50 16 NRL 36 50 
51 17 NRL 38 50 
52 18 NRL 42 50 
53 19 NRL 53 50 
54 20 NRL 59 50 
55 21 NRL 69 50 
56 22 NRL 70 50 
57 23 NRL 78 50 
75 
 
58 24 NRL 81 50 
59 25 NRL 82 50 
60 26 NRL 96 50 
61 27 NRL 111 50 
62 28 NRL 114 50 
63 29 NRL 118 50 
64 30 NRL 127 50 
65 31 NRL 128 50 
66 32 NRL 129 50 
67 33 NRL 133 50 
68 34 NRL 137 50 
69 35 NRL 142 50 
NI 31/100(31%)  
70 1 NRL 3 NI 
71 2 NRL 6 NI 
72 3 NRL 12 NI 
73 4 NRL 14 NI 
74 5 NRL 15 NI 
75 6 NRL 23 NI 
76 7 NRL 32 NI 
77 8 NRL 34 NI 
78 9 NRL 43 NI 
79 10 NRL 44 NI 
80 11 NRL 45 NI 
81 12 NRL 47 NI 
82 13 NRL 61 NI 
83 14 NRL 80 NI 
84 15 NRL 87 NI 
85 16 NRL 98 NI 
86 17 NRL 99 NI 
87 18 NRL 102 NI 
88 19 NRL 104 NI 
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89 20 NRL 106 NI 
90 21 NRL 109 NI 
91 22 NRL 112 NI 
92 23 NRL 116 NI 
93 24 NRL 131 NI 
94 25 NRL 132 NI 
95 26 NRL 138 NI 
96 27 NRL 140 NI 
97 28 NRL 141 NI 
98 29 NRL 74 NI 
99 30 NRL 75 NI 
100 31 NRL 113 NI 
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Appendix C. The PAGE figures of XCI patterns of Turkish JIA patients 
 
GEL1 
 
 
 
 
GEL2 
 
 
 
 
GEL3 
 
 
 
 
 
 
 
 
 
 
 
  M          05-166      05-167     05-168     05-169     05-170 
             51:49        56:44       58:42       56:44       78:22 
        
    M   05-171   05-172    05-173    05-174    05-175    05-176 
                       NI          NI        63:37        NI            NI           NI 
M      05-177         05-178         05-179        05-180        05-181 
          55:45           75:25            88:12           95:5               NI 
78 
 
 
GEL4 
 
 
 
 
 
GEL5 
 
 
 
 
 
GEL6 
 
 
 
              
 
 
 
 
 
 
 
 M     05-64          05-65       05-66        05-67        05-68        05-70 
          80:20           70:30     R(60:40)       NI             NI          69:31 
M     05-71        05-182      05-183     05-184      05-185       05-186 
        75:25          63:37        72:28          NI          51:49           80:20 
M       05-62           05-63           05-69           05-72         05-73 
          60:40            70:30           100:0           60:40           60:40 
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GEL7 
 
 
 
GEL8 
 
 
 
 
 
 
GEL9 
 
 
 
 
GEL10 
 
M        05-186            05-187              05-188             05-173 
             80:20             73:27                 95:5                 63:37 
 M    06-7          06-8          06-9         06-12       06-13        06-14 
         NI            90:10        71:29        76:24        95:5           95:5        
M                                                                             05-602 
                    61:39 JIA controls 
 M            05-601 
             64:36 
JIA controls 
80 
 
GEL11 
 
 
 
 
GEL12 
 
 
 
 
GEL13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  M      06-15         06-16       06-17         06-18       06-19        06-20 
              NI            93:7        51:49          81:19       54:46      80:20 
M      06-21        06-2        06-23        06-24       06-25      06-26 
         75:25           NI            NI         62:38        69:31       84:16 
06-27           06-28          06-29           06-30           06-31   
53:47           61:39          100:0            92:8            53:47            
81 
 
GEL14 
 
 
 
 
 
GEL15 
 
 
 
 
 
GEL16 
 
 
 
 
 
 
 
 
 
 
 
 
 M       06-33          06-34           06-35          06-36                  
              NI           57:43             NI               NI                                 
          06-41       06-43       06-44          06-45         06-46 
           NW         71:29       62:3           50:50         51:49 
 06-48                    06-51              06-52                 06-53           
52:48                     60:40              74:36                 50:50 
82 
 
 
GEL17 
 
 
 
 
 
GEL18 
 
 
 
 
GEL19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 M   07-1078  07-1079   07-1080    07-1081   07-1082   07-1083    07-1084 
        80:20      65:35      80:20       50:50         NI        70:30       60:40 
M  07-1085   07-1086   07-1087   07-1088  07-1089   07-1090    07-1031  
        50:50         60:40      80:20        NI      NI           NI        80:20 
         SSc 
M     06-32         06-37         06-38        06-61          06-63           06-80 
          NI            62:38          56:44 
JIA  controls 
83 
 
 
GEL20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M  07-1070      07-1074     07-1078     07-1080     07-1084      07-1087 
        80:20       75:25        85:15         80:20        70:30           75:25        
84 
 
Appendix D. The PAGE figures of XCI patterns of Turkish controls 
 
GEL1 
 
 
 
 
 
GEL2 
 
 
 
 
GEL3 
 
 
 
   M    05-334       05-335       05-337      05-339       05-341       05-342 
            NW            NW          55:45       60:40       58:42       72:28 
        
  M    05-343      05-344       05-345      05-346      05-347       05-349 
          50:50           NI              NI       57:43       68:32         54:46 
      
  M     05-329      05-330        05-33        05-332         05-333        05-336 
          53:47            NI          67:33         100:0           57:43          NW 
                 R(55:45) 
85 
 
GEL4
 
 
 
 
GEL5 
 
 
 
 
 
GEL6 
 
 
 
 
 
GEL7 
 
 
M    05-338        05-344     05-345       05-34       05-347       05-348 
        55:45             NI          NI          57:43        68:32         75:25 
M                          05-349       05-350      05-351       05-352 
      54:46         61:39        57:43            NI 
 M   05-353       05-354       05-35     05-356      05-357         05-358 
          NI            70:30        55:4       62:38       64:36         58:42 
  M  05-359      05-360     05-361      05-363     05-364      05-365  
         75:25        65:35         NI           51:49        63:37           NI 
86 
 
 
GEL8 
 
 
 
 
 
GEL9 
 
 
 
 
 
 
GEL10 
 
 
 
 
 
 
 
 
 M    05-366      05-36      05-369       05-370     05-371      05-372 
         64:36        55:45        85:15        85:15          NI          73:27 
M      05-336           05-362           05-367         05-373         05-374 
          55:45                NI               58:42          NI             61:39 
 M     05-375           05-376           05-377          05-378        05-379 
          73:27                NI              61:39           NI              NI 
87 
 
 
 
GEL11 
 
 
 
 
GEL12 
 
 
 
 
 
GEL13 
 
 
 
 
 
 
 
 M    05-582       05-58      05-584     05-585     05-586      05-587 
         58:42       88:12       54:46       66:34      55:45        75:25 
 M      05-588       05-589        05-592      05-593        05-594       05-595 
           82:18             NI            65:35        53:47          58:42          75:25 
M       05-596          05-598          05-599        05-600          05-602 
           63:37             50:50             75:25            NI               61:39 
                           JIA patient 
          
88 
 
GEL14 
 
 
 
 
 
GEL15 
 
 
 
 
 
 
GEL16 
 
 
 
 
 
 
 
 
 
 M                                  05-581      05-590        05-591     05-601 
                                      62:38        50:50          60:40      64:36 
             JIA patient 
   M   06-65         06-66         06-67       06-68         06-69         06-70 
          NI             73:27          55:4        75:25           70:30         78:22 
 M         06-71            06-72             06-73            06-74           06-75  
              82:18            100:0               NI               62:38            61:39       
89 
 
 
GEL17 
 
 
 
 
GEL18 
 
 
 
 
GEL19 
 
 
 
 
 
 
 
 
 
 
 M     06-55         06-56          06-57         06-58        06-59         06-60 
           NI            85:15           79:21         58:42         70:30         55:45  
M      06-62         06-64          06-76         06-7           06-78          06-79 
           NI               NW             NI          75:25           56:44          50:50 
M      06-32         06-3         06-38         06-61         06-63          06-80 
       60:40            98:2           51:49 
              R(NW) 
90 
 
Appendix E. The PAGE figures of XCI patterns of French RA patients 
 
GEL1 
 
 
 
 
GEL2 
 
 
 
 
GEL3 
 
 
 
 
GEL4 
 
 
 
 
 
 
 
M            SSc     PR 1  PR 2 
        90:10  80:20 
M PR 3        PR 5 PR 10          PR 13     PR 19 PR 20 
             80:20         60:40  70:30           75:25      90:10        NI 
M  PR 21         PR 24 PR 31          PR 37       PR 40 PR 47 
    NI             NI    NI           65:35        70:30    NI 
 M         PR 48   PR 51      PR 52                 PR 54 
           90:10    80:20       50:50        60:40 
91 
 
GEL5 
 
 
GEL6 
 
 
 
GEL7 
 
 
 
GEL8 
 
 
 
GEL9 
 
 
 
 
 
 
 M      PR 77   PR 78       PR 79     PR 82    PR 85      PR 88 PR 92 
 NI      NI         80:20      55:45        NI           NI   50:50 
 M      PR58     PR59       PR60       PR62       PR63         PR64      PR65 
           60:40        NI           NI 50:50      50:50 90:10         NI 
M      PR66   PR71       PR76 PR93    PR105      PR110 PR131 
          50:50   70:30        90:10    NI     50:50           NI    NI 
M    PR134  PR135      PR136     PR138    PR139     PR141 PR145 
        90:10      NI       90:10 NI       NI        55:45 50:50 
M      PR146                PR149      PR151      PR154    PR155   PR158 
 NI                       NI    NI       50:50       55:45    75:25 
92 
 
GEL10 
 
 
 
 
 
 
GEL11 
 
 
 
 
GEL12 
 
 
 
 
GEL13 
 
 
 
GEL14 
 
 
M      PR159                  PR160     PR161    PR164     PR165      PR167 
          55:45                  60:40        70:30        NI            R              NI  
M     PR169  PR170      PR172      PR177    PR179    PR184       PR185 
  ?   50:50        60:40  90:10         ?          ?     ? 
M    PR187    PR188        PR190             PR191   PR192 
 NI      90:10  90:10        ?                 NI 
M      PR179   PR184      PR185     PR187      PR188    PR190 PR191 
     ?    90:10        90:10   NI       90:10         ?     NI 
 
+ 
M      PR192       PR193  PR194        PR195    PR197        PR198 
             NI        50:50   90:10           60:40     80:20  50:50 
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GEL15 
 
 
 
 
 
 
 
GEL16 
 
 
 
 
GEL17 
 
 
 
GEL18 
 
 
 
 
 
 
 
 M       PR200            PR202              PR203      PR205 
        60:40             90:10     NI      50:50 
M  PR206           PR209            PR211        PR212     PR213 
    NI   NI  90:10          50:50        NI 
M     PR 1       PR 19    PR 48        PR 51   PR 52      PR 64      PR 76 
         90:10       90:10     90:10          80:20     50:50         90:10       90:10 
M      PR 79     PR 134    PR 136    PR165   PR 169  PR 177     PR 179 
          55:45         85:15        80:20      90:10      50:50     85:15        90:10 
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GEL19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M  PR 184   PR 185    PR 188    PR 190     PR 194   PR 202      PR 211 
      90:10       70:30        90:10       60:40       85:15      70:30        90:10 
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Appendix F. The PAGE figures of XCI patterns of French controls 
 
GEL1 
 
 
 
GEL2 
 
 
 
GEL3 
 
 
 
GEL4 
 
 
 
GEL5 
 
 
M    NRL3       NRL4     NRL6     NRL7       NRL9    NRL10       NRL12 
 NI   50:50        NI         80:20    60:40     55:45      NI 
M   NRL13     NRL14    NRL15    NRL22    NRL23    NRL24    NRL25 
        50:50           NI         NI            90:10      NI       80:20         55:45 
 M         NRL27    NRL28      NRL29      NRL30      NRL31      NRL32 
              55:45         90:10        60:40         80:20         55:45              NI 
 M         NRL 33     NRL 34  NRL 36 
  >90         NI     50:50 
M    NRL 37   NRL 38     NRL 40  NRL 41  NRL 42    NRL 43   NRL 44 
         60:40     50:50   NI  55:45      50:50  NI       NI 
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GEL6 
 
 
 
GEL7 
 
 
GEL8 
 
 
 
GEL9 
 
 
 
 
GEL10 
 
 
M  NRL 45    NRL 46    NRL 47   NRL 53      NRL 56   NRL 57      NRL 58 
         NI  80:20        NI        50:50   60:40        55:45   50:50 
M    NRL 59   NRL 61   NRL 66   NRL 68   NRL 69   NRL 70   NRL 72 
        50:50     NI       65:35        80:20    50:50       50:50  70:30 
  M       NRL 73   NRL 74     NRL 75    NRL76       NRL 77 
    60:40      90:10          NI     85:15  85:15 
  M        NRL 78        NRL 80           NRL 81     NRL 82       NRL 83 
    50:50   NI    50:50         85:15        80:20 
M      NRL 84      NRL 85     NRL 87      NRL 95     NRL 96     NRL 97 
       60:40          80:20 NI     55:45         50:50         55:45 
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GEL11 
 
 
 
GEL12 
 
 
 
GEL13 
 
 
 
GEL14 
 
 
 
 
GEL15 
 
 
 
 
 
 
 M        NRL 98      NRL 99             NRL 100          NRL 101    NRL 102 
   NI        NI                  70:30            70:30       NI 
  M     NRL 103    NRL 104    NRL 105    NRL 106   NRL 107   NRL 109     NRL 110 
 55:45          NI            90:10     NI      R          NI        >90 
M      NRL111    NRL112     NRL113     NRL114     NRL115       NRL116     NRL118 
            50:50         NI             NI  50:50       55:45  NI    50:50 
 M       NRL121    NRL122      NRL123    NRL124     NRL125     NRL126      NRL127 
 85:15      70:30          60:40         75:25    80:20          75:25  50:50 
M       NRL128     NRL129   NRL130   NRL131  NRL132      NRL133       NRL135 
            50:50     50:50       55:45         NI NI     50:50           55:45 
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GEL16 
 
 
 
GEL17 
 
 
 
GEL18 
 
 
 
GEL19 
 
 
 
 
GEL20 
 
 
  
M        NRL136     NRL137   NRL138    NRL139      NRL140      NRL141      NRL142 
  55:45        50:50          NI           55:45      NI           NI   50:50 
 M NRL28       NRL33      NRL40       NRL41      NRL42       NRL43        NRL44  
                 80:20          90:10         75:25         75:25          50:50          NI               NI 
M     NRL45        NRL46      NRL47       NRL53        NRL56        NRL57       NRL58 
            NI             80:20           NI              50:50           70:30          55:45           50:40 
M         NRL59          NRL66         NRL74          NRL75         NRL82          NRL107 
              50:50             65:35             NI                 NI               50:50              60:40 
 M   NRL110            NRL113             NRL121          NRL124            NRL126 
                 90:10                    NI                   85:15                 75:25                75:25 
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Appendix G. Frequency of PTPN22 genotypes in individuals with SSc 
    Code XCI PTPN22 DoB OoD 
Skewed             
1 1 03-894 98 C/C 1945 (58) 1989 
2 2 03-900 97 C/C 1940 (63) 1984 
3 3 03-899 96 C/C 1953 (50) 1998 
4 4 03-1110 >95 C/C 1932 (71) 1993 
5 5 03-962 >95 C/C 1946 (57) 1993 
6 6 03-954 >95 C/C 1965 (38) 2000 
7 7 03-1112 >95 C/C 1963 (40) 1997 
8 8 03-963 >95 C/C 1938 (65) 1998 
9 9 03-1101 >95 C/C 1941 (62) 1993 
10 10 03-1123 >95 C/C 1950 (53) 1990 
11 11 03-879 >95 C/T 1966 (37) 1991 
12 12 03-951 94 C/C 1986 (17) 2003 
13 13 03-948 92 C/C 1959 (44) 1989 
14 14 03-893 92 C/C 1936 (67) 1984 
15 15 03-881 >90 C/C 1971 (32) 1990 
16 16 03-953 90 C/C 1941 (62) 1995 
17 17 03-895 90 C/C 1941 (62) 1984 
18 18 03-886 90 C/T 1960 (43) 1994 
19 19 03-1120 90 C/C 1950 (53) 1983 
20 20 03-890 90 C/C 1956 (47) 1989 
21 21 03-878 88 C/C 1945 (58) 2000 
22 22 03-892 87 C/C 1965 (38) 1993 
23 23 03-880 87 C/C 1967 (36) 2002 
24 24 03-888 86 C/C 1952 (51) 1996 
25 25 03-952 85 C/C 1944 (59) 1984 
26 26 03-884 85 C/C 1944 (59) 1994 
27 27 03-1122 80 C/C 1949 (54) 1993 
28 28 03-885 80 C/C 1933 (70) 1993 
29 29 03-950 80 C/C 1936 (67) 1982 
30 30 03-943 80 C/C 1942 (61) 1999 
31 31 03-1104 80 C/C 1956 (47) 1983 
32 32 03-949 80 C/C 1975 (28) 2000 
33 33 03-1128 80 C/C 1983 (20) 2002 
Random             
34 1 03-944 50 C/C 1945 (48) 1987 
35 2 03-1113 65 C/C 1965 (38) 1994 
36 3 03-1114 55 C/C 1967 (36) 1995 
37 4 03-955 50 C/C 1947 (46) 1996 
38 5 03-887 50 C/C 1946 (47) 1989 
39 6 03-1103 50 C/C 1940 (43) 1993 
40 7 03-1132 55 C/C 1977 (26) 1993 
41 8 03-945 50 C/C 1979 (24) 2003 
42 9 03-898 50 C/C 1967 (36) 1998 
43 10 03-1117 50 C/C 1956 (47) 2001 
100 
 
44 11 03-947 55 C/C 1961 (42) 1988 
45 12 03-958 60 C/C 1976 (27) 1993 
46 13 03-957 60 C/C 1970 (33) 1991 
47 14 03-1111 60 C/C 1952 (49) 1991 
48 15 03-1115 55 C/C 1961 (42) 1989 
49 16 03-1118 55 C/C 1966 (37) 2000 
50 17 03-1125 50 C/C 1940 (63) 1978 
51 18 03-1126 65 C/C 1951 (52) 1993 
52 19 03-1127 50 C/C 1967 (36) 2000 
53 20 03-1131 55 C/C 1929 (74) 1999 
Not informative             
54 1 03-1105 NI C/C 1937 1998 
55 2 03-1116 NI C/C 1969 2000 
56 3 03-942 NI C/C 1969 1998 
57 4 03-1130 NI C/C 1932 1963 
58 5 03-897 NI C/C 1931 1982 
59 6 03-1102 NI C/C 1947 2002 
60 7 03-946 NI C/C 1945 1989 
61 8 03-1129 NI C/C 1949 1998 
62 9 03-883 NI C/C 1945 1991 
63 10 03-882 NI C/C 1964 1996 
64 11 03-961 NI C/C 1959 1993 
65 12 03-960 NI C/C 1968 1993 
66 13 03-1124 NI C/C 1956 1991 
Not Worked             
67 1 03-889 NW C/C 1947 1995 
68 2 03-896 NW C/C 1946 1991 
69 3 03-1119 NW C/C 1949 1969 
70 4 03-1121 NW C/C 1955 1990 
71 5 03-1106   C/T     
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Appendix H. Frequency of PTPN22 genotypes in individuals with AITD 
  
Code XCI PTPN22 DoB OoD 
Skewed             
1 1 04-121. >90 C/C 1957 1988 
2 2 04-127. >90 C/T 1975 2003 
3 3 04-198. >90 C/C 1935 2004 
4 4 04-221. >90 C/C 1958 2000 
5 5 04-226. >90 C/C 1963 2004 
6 6 04-250. >90 C/C 1967 1996 
7 7 04-254. >90 C/C 1941 2004 
8 8 04-128. >90 C/C 1960 2001 
9 9 04-138. >90 C/C 1962 1980 
10 10 04-205. >90 C/C 1927 2003 
11 11 04-233. >90 C/C 1967 1990 
12 12 04-244. >90 C/C 1963 1993 
13 13 04-136. >90 C/C 1975 2004 
14 14 04-214. 85-90 C/C 1921 2001 
15 15 04-225. 85-90 C/C 1936 1975 
16 16 04-98. 85-90 C/C 1956 2000 
17 17 04-132. 85-90 C/C 1960 2002 
18 18 04-131. 85-90 C/C 1944 2002 
19 19 04-105. 85-90 C/C 1978 1999 
20 20 04-218. 80-85 C/C 1941 1991 
21 21 04-108. 80-85 C/C 1952 1999 
22 22 04-107. 80-85 C/C 1948 1998 
23 23 04-208. 80-85 C/C 1960 1999 
24 24 04-223. 80-85 C/C 1956 1988 
25 25 04-110. 80-85 C/C 1960 1998 
Random             
26 1 04-137. 70 C/C 1932 1981 
27 2 04-203. 70 C/C 1961 2004 
28 3 04-213. 70 C/C 1947 1998 
29 4 04-228. 70 C/C 1953 2001 
30 5 04-103. 68 C/C 1962 1986 
31 6 04-248. 68 C/C 1951 1978 
32 7 04-92. 65 C/C 1971 1998 
33 8 04-251. 65 C/C 1941 1984 
34 9 04-253. 65 C/C 1965 2001 
35 10 04-199. 64 C/C 1950 2002 
36 11 04-256. 63 C/C 1982 2003 
37 12 04-240. 62 C/C 1975 2003 
38 13 04-257. 62 C/C 1973 2004 
39 14 04-112. 62 C/C 1952 1999 
40 15 04-139. 60 C/C 1959 2002 
41 16 04-99. 60 C/C 1961 1997 
42 17 04-95. 58 C/C 1975 2004 
43 18 04-96. 57 C/C 1939 1996 
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44 19 04-239. 57 C/C 1951 2003 
45 20 04-242. 57 C/C 1960 1999 
46 21 04-119. 57 C/C 1982 2001 
47 22 04-238. 55 C/C 1939 2002 
48 23 04-246. 55 C/C 1961 1996 
49 24 04-134. 55 C/C 1968 2004 
50 25 04-117. 55 C/C 1944 2004 
51 26 04-200. 54 C/C 1954 1992 
52 27 04-237. 54 C/C 1970 2004 
53 28 04-197 53 C/C 1961 1976 
54 29 04-229. 53 C/C 1938 ? 
55 30 04-123. 52 C/T 1963 1998 
56 31 04-196. 52 C/C 1956 1999 
57 32 04-231. 52 C/C 1964 2003 
58 33 04-247. 52 C/C 1962 2002 
59 34 04-255. 52 C/T 1974 1993 
60 35 04-102. 50 C/C 1964 2003 
61 36 04-118. 50 C/C 1972 2000 
62 37 04-129. 50 C/C 1982 1998 
63 38 04-204. 50 C/C 1949 2002 
64 39 04-215. 50 C/C 1950 2002 
65 40 04-202. 75 C/C 1968 2001 
66 41 04-220. 67 C/C 1955 1998 
67 42 04-206. 62 C/C 1946 1964 
68 43 04-211. 52 C/C 1950 2002 
69 44 04-212. 52 C/C 1958 2002 
70 45 04-93. 52 C/C 1960 2003 
71 46 04-88. 50 C/C 1979 2004 
72 47 04-201. 50 C/C 1971 2001 
73 48 04-224. 62 C/C 1950 2001 
Not informative             
74 1 04-89.   C/C 1927 2002 
75 2 04-90.   C/C 1984 2001 
76 3 04-94.   C/C 1960 2001 
77 4 04-100.   C/T 1965 2001 
78 5 04-106.   C/C 1961 2002 
79 6 04-113.   C/C 1978 2004 
80 7 04-115.   C/C 1960 2001 
81 8 04-122.   C/C 1948 1999 
82 9 04-124.   C/T 1982 2004 
83 10 04-126.   C/C 1955 1994 
84 11 04-130.   C/C 1960 2002 
85 12 04-209.   C/C 1971 2003 
86 13 04-216.   C/C 1954 2003 
87 14 04-217.   C/C 1948 2003 
88 15 04-227.   C/C 1965 2003 
89 16 04-234.   C/C 1971 2003 
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90 17 04-236.   C/C 1954 1994 
91 18 04-241.   T/T 1948 1994 
92 19 04-104.   C/C 1977 2004 
93 20 04-207.   C/C 1952 1990 
94 21 04-97.   C/C     
95 22 04-109.   C/C     
96 23 04-219.   C/C     
97 24 04-232.   C/T     
98 25 04-235.   C/C     
99 26 04-101.   C/C     
100 27 04-125.   C/C     
101 28 04-133.   C/C     
102 29 04-135   C/C     
103 30 04-245.   C/T     
104 31 04-249   C/C     
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Appendix I. Frequency of PTPN22 genotypes controls 
  
SAMPLE 
ID PTPN22 
1 03-733 C/C 
2 03-742 C/C 
3 03-745 C/C 
4 03-771 C/C 
5 03-772 C/C 
6 03-777 C/C 
7 03-732 C/C 
8 03-734 C/C 
9 03-738 C/C 
10 03-740 C/C 
11 03-760 C/C 
12 03-762 C/C 
13 03-767 C/C 
14 03-768 C/C 
15 03-769 C/C 
16 03-773 C/C 
17 03-776 C/C 
18 03-778 C/C 
19 03-813 C/C 
20 03-816 C/C 
21 03-817 C/C 
22 03-821 C/C 
23 03-822 C/C 
24 03-823 C/C 
25 03-826 C/C 
26 03-830 C/C 
27 03-832 C/C 
28 03-836 C/C 
29 03-839 C/C 
30 03-840 C/C 
31 03-846 C/C 
32 03-847 C/C 
33 03-850 C/C 
34 03-852 C/C 
35 03-855 C/C 
36 03-856 C/C 
37 03-860 C/C 
38 03-861 C/C 
39 03-862 C/C 
40 03-864 C/C 
41 03-815 C/C 
42 03-818 C/C 
43 03-819 C/C 
44 03-825 C/C 
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45 03-827 C/C 
46 03-828 C/C 
47 03-829 C/C 
48 03-834 C/C 
49 03-835 C/C 
50 03-837 C/C 
51 03-838 C/C 
52 03-842 C/C 
53 03-843 C/C 
54 03-848 C/C 
55 03-849 C/C 
56 03-851 C/C 
57 03-853 C/C 
58 03-854 C/C 
59 03-857 C/C 
60 03-859 C/C 
61 03-863 C/C 
62 03-735 C/T 
63 03-747 C/T 
64 03-833 C/T 
65 03-824 C/T 
66 03-844 C/T 
67 03-845 C/T 
68 03-841 T/T 
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Appendix J. Confirmation of PTPN22 genotypes by microarray analysis 
Code PTPN22 
 04-88. C/C AITD  
04-92. C/C AITD 
04-93. C/C AITD 
04-95. C/C AITD 
04-96. C/C AITD 
04-98. C/C AITD 
04-99. C/C AITD 
04-102 C/C AITD 
04-103 C/C AITD 
04-105 C/C AITD 
04-107 C/C AITD 
04-108 C/C AITD 
04-110 C/C AITD 
04-112 C/C AITD 
04-117 C/C AITD 
04-118 C/C AITD 
04-119 C/C AITD 
04-121 C/C AITD 
04-123 C/T AITD 
04-127 C/T AITD 
04-128 C/C AITD 
04-131 C/C AITD 
04-132 C/C AITD 
04-134 C/C AITD 
04-136 C/C AITD 
04-137 C/C AITD 
04-138 C/C AITD 
04-139 C/C AITD 
04-196 C/C AITD 
04-197 C/C AITD 
04-198 C/C AITD 
04-199 C/C AITD 
04-200 C/C AITD 
04-201 C/C AITD 
04-202 C/C AITD 
04-203 C/C AITD 
04-204 C/C AITD 
04-205 C/C AITD 
04-206 C/C AITD 
04-208 C/C AITD 
04-211 C/C AITD 
04-212 C/C AITD 
04-213 C/C AITD 
04-214 C/C AITD 
04-215 C/C AITD 
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04-218 C/C AITD 
04-220 C/C AITD 
04-223 C/C AITD 
04-224 C/C AITD 
04-226 C/C AITD 
04-228 C/C AITD 
04-229 C/C AITD 
04-233 C/C AITD 
04-237 C/C AITD 
04-238 C/C AITD 
04-239 C/C AITD 
04-242 C/C AITD 
04-244 C/C AITD 
03-890 C/C SSc 
04-129 C/C AITD 
04-225 C/C AITD 
04-231 C/C AITD 
04-240 C/C AITD 
03-878 C/C SSc 
03-880 C/C SSc 
03-881 C/C SSc 
03-884 C/C SSc 
03-885 C/C SSc 
03-886 C/T SSc 
03-887 C/T SSc 
03-888 C/C SSc 
03-892 C/C SSc 
03-893 C/C SSc 
03-893 C/C SSc 
03-895 C/C SSc 
03-898 C/C SSc 
03-899 C/C SSc 
03-900 C/C SSc 
03-943 C/C SSc 
03-944 C/C SSc 
03-945 C/C SSc 
03-947 C/C SSc 
03-1117 C/C SSc 
03-1118 NW SSc 
03-1120 C/C SSc 
03-1122 C/C SSc 
04-246 C/C AITD 
04-247 C/C AITD 
04-248 C/C AITD 
04-250 C/C AITD 
04-251 C/C AITD 
04-253 C/C AITD 
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04-254 C/C AITD 
04-255 C/T AITD 
04-256 C/C AITD 
04-257 C/C AITD 
03-747 C/T Control 
03-760 C/C Control 
03-762 C/C Control 
03-767 C/C Control 
03-768 C/C Control 
03-769 C/C Control 
03-773 C/C Control 
03-776 C/C Control 
03-778 C/C Control 
03-948 C/C SSc 
03-949 C/C SSc 
03-950 NW SSc 
03-951 C/C SSc 
03-952 C/C SSc 
03-954 C/C SSc 
03-955 C/C SSc 
03-958 C/C SSc 
03-962 C/C SSc 
03-963 C/C SSc 
03-1101 C/C SSc 
03-1103 C/C SSc 
03-1104 C/C SSc 
03-1110 C/C SSc 
03-1111 C/C SSc 
03-1112 C/C SSc 
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Appendix K. The gel figures of frequencies of PTPN22 genotypes 
 
GEL1 DIGESTION OF PPTN22 LOCUS WITH XcmI  OF HT 
 
 
GEL2  DIGESTION OF PPTN22 LOCUS WITH XcmI  OF HT 
 
 
GEL3 DIGESTION OF PPTN22 LOCUS WITH XcmI  OF HT 
 
 
 
 
 
 
 
 
   04-97   123    124   125    126    127   128   129    130    131    132   133   134   135 
04-136  137    138   139   196   197    198    19    200     201   202   203    204    205 
  04-88  89   90   92   93   94   95   96   99  100 101 103  104 105 106  108 109 110 112 113 
04-115 117 119 121  122  206 207 208 209  211 212 213 214 215 216  217 218 219  220 
04-102  107  118  221  223 224  225 226  227  228 229      231 232  233  234  235  236 237 
04-238  239  240   241  242   244  245  246  247  248   249  250   251  253  254   255   256   257 
   C/C   C/T    C/T    C/C    C/C   C/T    C/C    C/C    C/T   C/C    C/C    C/C    C/C    C/C 
C/C   C/C    C/C     C/C    C/C    C/C    C/C   C/C   C/C   C/C     C/C    C/C    C/C   C/C 
  C/T C/T  C/C C/C C/C C/C C/C C/C C/C C/T C/C  C/T C/C C/C  C/C C/C C/C C/C C/C C/C 
C/C C/C   C/T C/C C/C C/C C/C C/C  C/C C/C C/C C/C C/C C/C C/C C/C C/C C/C  C/T 
  C/C  C/C  C/C C/C  C/C C/C C/C C/C C/C  C/C C/T         C/C  C/T  C/C C/C  C/C C/C C/C 
C/C  C/C C/C  T/T C/C C/C  C/T  C/C C/C  C/C C/C C/C  C/C  C/C  C/C T/T C/C  C/C 
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GEL4  DIGESTION OF PPTN22 LOCUS WITH XcmI  OF CONTROL 
 
 
 
GEL5  DIGESTION OF PPTN22 LOCUS WITH XcmI  OF CONTROL 
 
 
 
GEL6  DIGESTION OF PPTN22 LOCUS WITH XcmI  OF CONTROL 
 
 
 
 
 
 
 
 
    03-733    03-813     03-815     03-816    03-817   03-818   03-819    03-821 
03-822  823   824   825  826   827   828   829   830   832   833   834  835   836   837   838 
  03-839   840    842    843    845    846   848    849    850    851    852    853    855     857   859      
03-862   863              05-17  05-18  05-20 05-21 05-23           05-27   05-29  05-31  05-32  05-33  05-34 
   C/C     C/C     C/C      C/C       C/C      C/C     C/C      C/C 
 C/C   C/C    C/C  C/C    C/C   C/C   C/C   C/C   C/C  C/C    C/T   C/C   C/C   C/C   C/C  C/C 
 C/C   C/C   C/C   C/C    C/C    C/C   C/T   C/C   C/C   C/C   C/C   C/C   C/C   C/C   C/C    
  C/C  C/C             C/C    C/C    C/C    C/C    C/C            C/C    C/C    C/C   C/C    C/C   C/C 
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GEL7 DIGESTION OF PPTN22 LOCUS WITH XcmI  OF SSC 
 
 
 
GEL8  DIGESTION OF PPTN22 LOCUS WITH XcmI  OF SSC 
 
 
 
 
GEL9 DIGESTION OF PPTN22 LOCUS WITH XcmI  OF SSC 
 
 
 
 
GEL10  DIGESTION OF PPTN22 LOCUS WITH XcmI  OF SSC 
 
 
 
 
 
   C/C      C/T        C/C       C/C       C/C      C/C      C/C       C/C        C/T      C/C      C/C 
03-878    879      880       881       882      883      884      885       886        887      888 
   C       C       C         C        C       C       C       C       C      C         C        C        C       C 
    03-889   890     892     894    895      896    897     898     899     946     947    948      949     950 
03-890  900   942   943  944   945   951  952  953   954   955   957  958  960   961   962  963 1101 1102 
     C     C      C     C     C     C     C     C      C     C      C      C     C     C      C    C     C      C     C 
            03-1103 1104 110  1106  1107 1108 1109 1110  1111 1112  1113 1114 11151116 1117  1118 1119 1120 1121 1122 
  C     C      C      C    C     C     C     C    C     C     C    C    C     C    C             C     C     C     C 
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GEL11   DIGESTION OF PPTN22 LOCUS WITH XcmI  OF CONTROLS 
 
 
 
GEL12  DIGESTION OF PPTN22 LOCUS WITH XcmI  OF CONTROLS 
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Increased Frequency of Extremely Skewed
X Chromosome Inactivation in Juvenile Idiopathic Arthritis
Elif Uz,1 Chigdem Mustafa,1 Rezan Topaloglu,2 Yelda Bilginer,2 Ali Dursun,2
Ozgur Kasapcopur,3 Seza Ozen,2 Aysin Bakkaloglu,2 and Tayfun Ozcelik1
Objective. Juvenile idiopathic arthritis (JIA) is a
childhood rheumatic disease of unknown etiology. Two
subgroups of JIA, i.e., oligoarticular and polyarticular,
are thought to have an autoimmune component, and
show a higher female:male ratio. Skewed X chromosome
inactivation (XCI) has previously been shown to be
associated with scleroderma and autoimmune thyroid-
itis, 2 autoimmune disorders occurring predominantly
in females. This study was undertaken to extend the
analysis to the pediatric age group and to determine the
XCI profiles of patients with JIA.
Methods. A polymorphic repeat in the androgen
receptor gene was genotyped to determine XCI status in
81 female patients with JIA (21 with polyarticular
disease and 60 with oligoarticular disease) and 211
healthy female controls. DNA obtained from venous
blood samples was used for this analysis.
Results. Informative data were obtained on 62 JIA
patients and 155 controls. Skewed XCI was observed in
14 patients (22.6%) and 11 controls (7.1%) (P 0.0036),
and extreme skewing was apparent in 8 patients (12.9%)
and 2 controls (1.3%) (P  0.0008).
Conclusion. Our findings in the present study
indicate that skewed XCI may be a risk factor for the
occurrence of autoimmune disorders, including JIA.
Juvenile idiopathic arthritis (JIA) is a broad term
for a group of diseases characterized by chronic inflam-
mation of 1 or more joints persisting longer than 6
weeks. It affects children before the age of 16, and its
etiology is unknown. The International League of Asso-
ciations for Rheumatology (ILAR) criteria set is the
most recent accepted classification scheme (1). It is
based on the number of affected joints and the presence
of systemic symptoms. According to the ILAR classifi-
cation, JIA is heterogeneous, with at least 6 subgroups:
1) systemic arthritis, 2) polyarthritis (rheumatoid factor
positive and rheumatoid factor negative), 3) oligoarthri-
tis (extended and persistent), 4) psoriatic arthritis, 5)
enthesis-related arthritis, and 6) undifferentiated arthri-
tis. Autoimmunity is particularly associated with the
polyarthritis and oligoarthritis subgroups, and girls are
more frequently affected than boys (female:male ratio
2–3:1) (2). Interestingly, an association between Turner’s
syndrome and juvenile arthritis has been reported (3).
It has long been recognized that hormone levels
and pregnancy-related fetal–maternal microchimerism
may influence the occurrence of autoimmunity (4,5).
Recently, our group and others observed that skewed X
chromosome inactivation (XCI) could be a novel pre-
disposition factor (6–8). Among these factors, XCI
could be considered a particularly attractive etiologic
candidate in JIA, since the onset of the disease is before
puberty, excluding the risks associated with hormone
levels and fetal microchimerism. In order to test the
hypothesis that XCI may play a role in the pathogenesis
of JIA, we determined the X chromosome inactivation
profiles of patients with JIA and control subjects.
PATIENTS AND METHODS
Patients. Eighty-one girls diagnosed as having JIA
according to the ILAR criteria and 211 healthy girls with no
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history of autoimmune disorders or cancer (control group;
mean  SD age 13  4 years) were included in the study. The
medical files of the parents were not available for analysis. The
mean  SD age of the JIA patients was 10  5 years, and the
mean age at the time of disease onset was 6  4 years.
Twenty-one of the JIA patients had polyarticular disease and
60 had oligoarticular disease. The following clinical data were
obtained on all patients: age, age at diagnosis, type of JIA,
disease duration, and treatment regimens. Informed consent
was obtained from all subjects (or legal guardians of subjects
who had not reached age of majority). The ethics committee of
Hacettepe University approved the study protocol.
X chromosome inactivation assay. The highly polymor-
phic CAG repeat on the first exon of the androgen receptor
gene was genotyped, as described elsewhere (6,8,9), to deter-
mine the XCI status of the patients and controls.
Statistical analysis. The significance of differences in
results between the JIA patients and the control subjects was
determined by Fisher’s exact test.
RESULTS
Findings on XCI status were informative in 62 of
the 81 JIA patients (76.5%) and in 155 of the 211
controls (73.5%). The individuals whose alleles could
not be distinguished adequately were not included in the
densitometric analysis and were categorized as having
noninformative results. Skewed XCI (80% skewing)
was observed in 14 of the 62 patients with informative
results (22.6%), and in 11 of the 155 controls with
informative results (7.1%) (P  0.0036). Extremely
skewed XCI ratios (90% skewing) were seen in 8 of
the 62 patients (12.9%), but in only 2 of the controls
(1.3%) (P  0.0008) (Table 1). Studies in large cohorts
have firmly established that extremely skewed XCI is
rare in the general population (10).
It has been reported that years after exposure to
an immunosuppressive agent, XCI ratios in feline hema-
topoietic cells may be skewed (11). We therefore inves-
tigated correlations between XCI ratios and treatment
regimens in the patients. All of the patients were receiv-
ing some treatment at the time of sample collection.
Fourteen were receiving nonsteroidal antiinflammatory
drugs (NSAIDs), 11 were receiving methotrexate
(MTX), 10 were receiving MTX plus NSAIDs, and 9
were receiving intraarticular corticosteroids plus
NSAIDs. The remaining 18 were receiving various com-
binations of these and other drugs. Clinical details on
the 62 patients are shown in Supplementary Table 1,
available on the Arthritis & Rheumatism Web site at
http://www3.interscience.wiley.com/journal/76509746/
home. Among the patients with skewed XCI, 7 (50%)
had received treatment with immunosuppressive agents
for 6–10 years, and 1 (7%) had received immunosup-
pressive treatment for 2 years. The remaining 6 had
received antiinflammatory treatment alone. Among the
patients with random patterns of XCI, 27 (56.3%) had
received immunosuppressive treatment for 2 years. At
any stage of their treatment, suspended leukopenia or
bone marrow ablation was not observed in any of the
patients. These results, along with previous observations
(6,8), indicate that it is unlikely that immunosuppressive
therapy caused skewed XCI in the patients.
DISCUSSION
Autoimmune disorders are complex and affect
5% of the world population (12). A diverse group of
autoimmune diseases, including rheumatoid arthritis
and JIA, affects females more frequently than males (2).
In this study, we observed skewed XCI patterns in
peripheral blood mononuclear cells of a significant
proportion of female subjects with JIA, with 22.6% in
the 80% skewing range (versus 7.1% of controls) and
12.9% in the 90% skewing range (versus 1.3% of
controls). These results support the hypothesis that loss
of XCI mosaicism in females may constitute a risk factor
for the development of JIA.
At present, the nature of the association between
skewed XCI and breakdown of self tolerance, as exem-
plified in this study on JIA and previous observations on
scleroderma (6) and autoimmune thyroiditis (7,8,13), is
not known. We propose that deleterious X-linked mu-
tations could influence the survival of cells that inacti-
vate a normal X chromosome and leave the mutant X
transcriptionally active. Since cells that inactivate the
mutant X would be immune to the deleterious effects of
the putative mutations, females could tolerate them by
losing their mosaic status for X-linked gene expression
(14,15). An interesting aspect of extremely skewed XCI
is that it does not lead to the breakdown of self tolerance
Table 1. Proportion of the juvenile idiopathic arthritis (JIA) patients
and controls with skewed X chromosome inactivation*
% skewing
JIA patients
(n  62)
Controls
(n  155)
90 8 (12.9) 2 (1.3)
80–89 6 (9.7) 9 (5.8)
70–79 13 (21.0) 29 (18.7)
60–69 18 (29.0) 39 (25.2)
50–59 17 (27.4) 76 (49.0)
* Values are the number (%). For 80% skewing, P  0.0036 (odds
ratio 3.81 [95% confidence interval 1.65–8.83]); for 90% skewing,
P 0.0008 (odds ratio 11.33 [95% confidence interval 2.62–48.48]), by
Fisher’s 2-tailed exact test.
X CHROMOSOME INACTIVATION IN JIA 3411
in all females. This suggests that breakdown of self
tolerance may require 2 distinct events on the X chro-
mosome: first, a lethal mutation leading to loss of
mosaicism, and second, “heterozygosity” for the nonsyn-
onymous variants of the putative critical genes. To the
best of our knowledge, this is the first study that has
shown an association between skewed XCI and a pedi-
atric form of an autoimmune disease, i.e., JIA.
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EDITORIAL
The Price of Silence
Nathalie C. Lambert
Female predisposition to autoimmunity
It has long been recognized that the prevalence
of autoimmune diseases is greater in women than in
men. This gender gap is often ascribed to hormonal
differences and gender distinction in immune responses
(i.e., higher number of absolute CD4 cells in women
than in men) (for review, see ref. 1). Fetal microchimer-
ism, an unavoidable sequel of pregnancy which results
in persistence of fetal cells in the mother, is also often
discussed and described as a potential mechanism of
“auto”-immunity in women, particularly in systemic scle-
rosis (for review, see ref. 2). While all the above
possibilities are of importance, another gender differ-
ence, of relevance for autoimmune disorders, is X
chromosome inactivation (3,4).
Silencing of 1 X chromosome: a female particularity
X chromosome inactivation (XCI) is a dosage
compensation mechanism used by mammals to ensure
that X chromosome gene expression is equalized in XX
females and XY males (3). Early in female embryonic
life, 1 of the 2 X chromosomes is randomly silenced,
except in 15% of genes including those corresponding
to functional X and Y homologs (5). XCI depends on
the presence of the X-inactive specific transcript (XIST)
gene, which codes not for a protein but for a functional
RNA expressed exclusively in cells with 1 X chromo-
some. At cell interphase, XIST RNA coats the X
chromosome on which it is produced, to randomly
inactivate either the paternal or the maternal X chro-
mosome (6). As a consequence, females are a mosaic of
2 cell lines, 1 expressing maternal X-linked and the other
expressing paternal X-linked genes, with a ratio close to
50:50 when XCI is random.
Skewed silencing and immunologic consequences
However, skewing, defined as a deviation from
the 50:50 ratio, can occur. The most common technique
used to analyze XCI patterns is genotyping of a highly
polymorphic CAG repeat in the human androgen recep-
tor (AR) gene. Hpa II and Hha I enzyme restriction
sites, located 100 bp from this polymorphic short
tandem repeat, are methylated on the inactive X chro-
mosome and nonmethylated on the active X chromo-
some. Polymerase chain reaction (PCR) amplification
across this region permits the distinguishing of 2 ampli-
cons with different sizes, corresponding to maternal and
paternal X alleles (among informative subjects heterozy-
gous for AR) (7). After enzyme digestion, PCR ampli-
fication is possible only for the methylated (uncut) X
chromosome. Densitometric analysis of the 2 alleles
indicates the inactivation status of 1 allele compared
with the other and reveals the percentage of XCI
skewing. A skewed result is defined as 1 allele being
inactivated at 75%. Extreme skewing represents an
inactivation of 90%.
Women with extremely skewed XCI host a large
population of cells with one X chromosome inactivated
and a small population with the other X chromosome
inactivated. Under such circumstances, rare cells from
the smaller population would fail to be sufficiently
expressed in the thymus, and this would lead to the
escape of X-linked self antigens from presentation. This
represents an interesting explanation for autoimmunity,
that was first speculated by Stewart as a possible mech-
anism of predisposition to systemic lupus erythematosus
(SLE) (4). This hypothesis has been tested by several
research groups in different autoimmune disorders.
Contrary to expectations, however, the frequency of
skewing of XCI is not significantly increased among
women with SLE (8). However, scleroderma and auto-
immune thyroiditis are among the top 10 diseases for
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which skewed XCI is significantly increased (9–12).
Most studies have been conducted on adult women, and
analyses of pediatric cohorts are rare.
Bias of XCI in juvenile idiopathic arthritis
In this issue of Arthritis & Rheumatism, Uz and
colleagues describe a bias in XCI in peripheral blood
mononuclear cells of patients with juvenile idiopathic
arthritis (JIA), as determined by AR genotyping (13).
The analysis of a young cohort is of interest because
reduction in sex ratio (male:female) is a characteristic
of autoimmune disorders not only with adult onset, but
also with juvenile onset (7).
A prior study of patients with pediatric auto-
immune diseases conducted by Chitnis et al in 2000, as
part of a large study of female patients with a variety
of autoimmune diseases, did not show a bias of XCI in
patients with juvenile rheumatoid arthritis (JRA) (8).
One possible explanation for the difference in results
between that study and the one by Uz et al is that clinical
definitions were not necessarily concordant. Moreover,
only 18 patients with JRA were tested in the study by
Chitnis and colleagues.
XCI bias increases with age
Although skewed XCI is sometimes observed in
the general population, extreme skewing is rarely seen.
Uz and colleagues’ finding that 12.9% of patients with
JIA had extreme skewing, compared with 1.3% of
controls, is of great importance. Comparison with a
group of pediatric controls reinforces their study results.
Indeed, several studies have shown that skewing
of XCI increases significantly in the blood cells of
females from the neonatal period to old age. Contro-
versy surrounding this issue, due to the use of different
methods of analysis, appears to have been resolved in a
recent study in which the age effect was confirmed with
the use of independent methodologies (14). The inci-
dence of skewing triples from birth to older age and
raises the question of whether it may be an indicator of
hematopoietic malignancies in the elderly (14). Most of
the “war” for choosing which X chromosome to inacti-
vate takes place in early embryonic life and results in a
stable mosaic status. However, correlation of skewing
with age suggests that this status is not so stable, and that
some “battles” are still readjusting this choice in late
adult life, at least in the blood.
XCI and hormones
Because the onset of JIA occurs before puberty,
it seems unlikely that the sex ratio could be explained by
hormone differences. Then, could other genetic predis-
positions make sense, bearing in mind the influence of
age on the outcome of genotyping results? Unfortu-
nately, there is, to my knowledge, no analysis of XCI
skewing in female subjects grouped according to hor-
mone levels, e.g., prepuberty, puberty, adults before
menopause, and adults after menopause. Although the
age of a child does not distinguish pre- from postpuberty
with certitude, it provides an indication, and the very
detailed supplemental table in the report by Uz et al (13)
does not reveal notable differences in skewing according
to age since, among the 8 patients found to have extreme
skewing, some had very early JIA onset and others a
postpubertal onset.
XCI is not influenced by treatment
Another issue addressed in the study by Uz and
colleagues is whether exposure to immunosuppressive
agents could influence the XCI profile, as previously
reported to occur in feline hematopoietic cells (15); in
humans, immunosuppressive agents do not seem to be
responsible for the extreme skewing observed in some
autoimmune diseases. Indeed, this is not the first at-
tempt by this group to assess the effect of immunosup-
pressive drugs on XCI: in an earlier study showing XCI
bias in women with scleroderma, Ozcelik et al demon-
strated that patients with rheumatoid arthritis who were
receiving similar treatment regimens did not exhibit
similar skewing (9). In the present study (13) they again
excluded a possible effect of immunosuppressive therapy
by showing that both the skewed and the random XCI
profiles were represented among the patients who had
received immunosuppressive therapies.
Rupture of tolerance to X-encoded genes
Ozcelik and colleagues’ team has been studying
mosaicism in autoimmunity for several years now. Like
other investigators, they have considered a potential
mechanism through which lack of exposure to self
antigen could occur in women with loss of mosaicism.
This mechanism implies that defective tolerance from
skewed XCI should be directed at X-linked antigens that
are polymorphic and heterozygous. This also suggests
that extreme skewing does not necessarily lead to auto-
immunity in individuals homozygous for such genes. But
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the reason XCI is biased in some autoimmune diseases
is still unknown. There are numerous causes of skewed
XCI, such as X-linked mutation affecting cell survival as
initially found in female carriers of specific X-linked
lethal mutations, XIST mutations, and balanced
X/autosome translocations perturbing the mechanism of
XCI (for review, see ref. 16).
Nevertheless, although extremely skewed XCI is
rare and is associated with autoimmune diseases, it does
not lead to the breakdown of self tolerance in all women.
Uz et al (13) propose that breakdown of self tolerance
requires the coinheritance of 2 distinct events on the X
chromosome. First, an X-linked mutation affecting cell
survival would lead to the extreme inactivation of the X
chromosome carrying such a mutation and lead to “loss
of mosaicism” (Figure 1). Then X chromosomes would
carry an allelic variant of the putative critical gene,
leading to autoimmunity because of the loss of mosa-
icism through lack of thymic exposure.
Such a scheme would explain why extensive ge-
nome screening during the past decade has resulted in
the identification of several susceptibility genes for
different autoimmune diseases, but often with weak
odds ratios. Females with loss of mosaicism may still
exhibit, in their genome, all that is necessary to avoid
susceptibility to autoimmunity, and therefore, an X
genome scan would not necessarily reveal their disad-
vantage.
Would the phenotype and the origin of inactivated
cells be of importance?
Our understanding of XCI is still incomplete, and
several essential questions remain. For example, al-
though several groups have demonstrated that the great-
est amount of X chromosome skewing is often observed
in peripheral blood, no detail on the phenotype of cells
has been reported. In prior studies on X monosomy,
cells losing their X chromosome were more often from
the adaptive immune system (B and T cells) than from
the innate system (natural killer cells, monocytes, poly-
morphonuclear cells) (17). Would this observation hold
for XCI, and if so, what would be its significance?
Moreover, is the paternal or maternal X chromosome
preferentially active? In a recent study on scleroderma,
Uz et al showed that maternal-origin X chromosome is
more often inactive than that of paternal origin (10).
Although the number of individuals tested was small,
this observation warrants further investigation and em-
phasizes the need to determine the parental origin of the
inactivated X chromosome to investigate the role of
imprinting. Interestingly, several genes known to be
crucial for the maintenance of immune tolerance and
hormone levels are located on the X chromosome. This
might close the loop regarding the gender gap in prev-
alence of autoimmunity.
Other nonexclusive mechanisms involving X
chromosome
The finding of extremely skewed XCI in juvenile
idiopathic arthritis provides an incentive to further
investigate the X chromosome field. For example, hap-
loinsufficiency of X-linked genes is an attractive candi-
date and has its roots in the aneuploidy of the X
chromosome, as in Turner’s syndrome and the recently
described X chromosome monosomy, both associated
with increased susceptibility to autoimmune disorders
(17,18). The reported association of Turner’s syndrome
with juvenile arthritis (18) suggests that, reciprocally,
these patients exhibit a higher rate of monosomy, as
observed in patients with scleroderma and autoimmune
thyroid disease. Fluorescence in situ hybridization stud-
ies in JIA patients with noninformative AR genotyping
results may reveal that the lack of information is due to
X monosomy rather than to homozygosity for the CAG
repeat. This has not yet been investigated and merits
further attention.
Figure 1. Proposed mechanisms by which heterozygosity and mono-
allelic expression of X-linked genes lead to autoimmunity. 1, A
deleterious X-linked mutation (represented in black) would lead to
extreme inactivation of the X chromosome carrying such a mutation
and lead to loss of mosaicism. Inactive X chromosomes are schemat-
ically coated with a black bar. 2, Presence of a polymorphic X-linked
gene (alleles represented in green and red) would trigger a lack of
thymic presentation of the rare cells in which the allele represented in
red is active. Only women heterozygous for that gene, and not
homozygous women, would have autoimmune disorders.
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Losing an advantage
Females have the privilege of having 2 X-linked
alleles at the same locus, rendering a copy in reserve on
1 X chromosome in case of a gene mutation on the
other. This is an advantage, but only when mosaicism is
retained. No single unifying hypothesis can explain the
pathogenesis of JIA, but the newly reported findings by
Uz et al (13) make us aware that biased X chromosome
silencing likely contributes to autoimmunity. This is the
price of silence.
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Abstract
Introduction The majority of autoimmune diseases such as
rheumatoid arthritis (RA) and autoimmune thyroid diseases
(AITDs) are characterized by a striking female predominance
superimposed on a predisposing genetic background. The role
of extremely skewed X-chromosome inactivation (XCI) has been
questioned in the pathogenesis of several autoimmune
diseases.
Methods We examined XCI profiles of females affected with RA
(n = 106), AITDs (n = 145) and age-matched healthy women (n
= 257). XCI analysis was performed by enzymatic digestion of
DNA with a methylation sensitive enzyme (HpaII) followed by
PCR of a polymorphic CAG repeat in the androgen receptor
(AR) gene. The XCI pattern was classified as skewed when
80% or more of the cells preferentially inactivated the same X-
chromosome.
Results Skewed XCI was observed in 26 of the 76 informative
RA patients (34.2%), 26 of the 100 informative AITDs patients
(26%), and 19 of the 170 informative controls (11.2%) (P <
0.0001; P = 0.0015, respectively). More importantly, extremely
skewed XCI, defined as > 90% inactivation of one allele, was
present in 17 RA patients (22.4%), 14 AITDs patients (14.0%),
and in only seven controls (4.1%, P < 0.0001; P = 0.0034,
respectively). Stratifying RA patients according to laboratory
profiles (rheumatoid factor and anti-citrullinated protein
antibodies), clinical manifestations (erosive disease and
nodules) and the presence of others autoimmune diseases did
not reveal any statistical significance (P > 0.05).
Conclusions These results suggest a possible role for XCI
mosaicism in the pathogenesis of RA and AITDs and may in part
explain the female preponderance of these diseases.
Introduction
It is postulated that the paternal and maternal antigens will be
recognized by the immune system within the thymus, and T
cells that have a high affinity for such antigens will be deleted
by apoptosis [1-3]. The lack of exposure to a self-antigen in the
thymus may lead to the presence of autoreactive T cells and
increase the risk of autoimmunity [4]. In female mammalian
cells, one of the two X-chromosomes is inactivated in early
embryonic life [5]. Thus, females are mosaics for two cell pop-
ulations, cells with either the paternal or the maternal X in the
active form. X-chromosome choice is assumed to be random,
and the result is generally 50% of cells expressing the paternal
and the remaining 50% expressing the maternal genes [6]. A
skewed X-chromosome inactivation (XCI) is a deviation from
this ratio and is arbitrarily defined, for example, as a pattern
where 80% or more of the cells inactivate the same X-chromo-
some [7]. This deviation may be the result of chance or genetic
factors involved in the XCI or a selection process [8]. ThePage 1 of 8
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where by X-linked self-antigens may escape presentation in
the thymus or in other peripheral sites that are involved in tol-
erance induction [9,10]. This has become an attractive candi-
date mechanism for breakdown of self-tolerance in
autoimmune diseases. An association between skewed XCI
and scleroderma was recently reported [11]. A higher fre-
quency of a skewed XCI pattern was found in patients affected
with autoimmune thyroid diseases (AITDs) compared with
healthy controls, indicating that skewed XCI may be associ-
ated with a predisposing factor for the development of AITDs
[12-14]. It was therefore of interest to study if there is an asso-
ciation between skewed XCI and rheumatoid arthritis (RA) as
a non-organ-specific and AITDs as an organ-specific autoim-
mune disease. We investigated the peripheral blood XCI pat-
terns of 106 females affected with RA, 145 females affected
with AITDs and 257 controls in the Tunisian and Turkish pop-
ulations. Extremely skewed XCI was found in the blood sam-
ples of female patients affected with RA and AITDs supporting
the role of skewed XCI in female predisposition to autoimmune
diseases.
Materials and methods
Patients and controls
RA sample
One hundred and six Tunisian women affected with RA were
recruited into the study. All patients fulfilled the 1987 Ameri-
can College of Rheumatology criteria for RA [15]. A rheuma-
tologist university fellow (ZB) reviewed all clinical data. The
mean age was 47.6 ± 13.4 (mean ± standard deviation (SD))
years. The duration of the symptoms was 15 ± 8.9 years. The
mean age of diagnostic was 40.3 ± 12 years. Among 106 RA
patients, 65 were rheumatoid factor (RF) positive (61.3%), 70
were anti-citrullinated protein/peptide antibodies (ACPA) pos-
itive (66%), 15 presented with nodules (14.1%), and 70 pre-
sented with erosive disease (66%). Fifteen patients had
another accompanying autoimmune diseases such as Sjö-
gren's syndrome, type 1 diabetes, or autoimmune thyroid dis-
eases.
AITDs sample
One hundred and forty-five Tunisian women affected with
AITDs were included in the study. There were a total of 58
patients with Graves' disease (GD) and 87 patients with
Hashimoto's thyroiditis (HT), which include 40 patients with
the goitrous form. The mean age was 46.5 ± 14.5 years for
AITDs patients (49.3 ± 13 years in HT patients and 44.6 ± 14
years in GD patients). The duration of the symptoms was 7.5
± 4.6 years among the AITDs patients (6.8 ± 4.8 years in HT
patients and 7.2 ± 4 years in GD patients). The mean age of
diagnosis was 37.9 ± 15.1 years. The diagnosis of GD was
based on the presence of biochemical hyperthyroidism as indi-
cated by a decrease of thyroid-stimulating hormone (TSH), an
increase of T4 levels, and positive TSH receptor antibody, in
association with diffuse goiter or the presence of exophthal-
mos. The diagnosis of HT was based on the presence of thy-
roid hormone replaced primary hypothyroidism, defined as a
TSH level above the upper limits associated with positive titers
of thyroid autoantibodies (anti-thyroglobulin and/or anti-thyroid
peroxidase) and with or without a palpable goiter.
Control group
Caucasian females, comprised of 97 Tunisian and 160 Turkish
healthy unrelated volunteers, served as controls in our studies.
The mean (± SD) age at analysis was 43.5 ± 15.3 years and
35 ± 9.9 years for Tunisian and Turkish controls, respectively.
There was no clinical evidence or family history of autoimmune
disease and inflammatory joint disease.
All individuals (patients and controls) provided informed con-
sent. The ethics committee of the Centre Hospitalo-Universi-
taire Hédi Chaker de Sfax, Tunisie, and the Bilkent University,
Ankara, Turkey approved the study protocol.
Methods
Autoantibodies analysis
In AITDs patients, thyroid autoantibodies (anti-thyroglobulin
and anti-thyroid peroxydase) were measured by ELISA and
indirect immunofluorescence using commercially available kits
Table 1
Proportion of RA and AITDs patients and controls with skewed X-chromosome inactivation
Number (%) observed with skewed
Degree of skewing (%) RA (n = 76) AITDs (n = 100) Control females (n = 170)
90+ 17 (22.4) 14 (14) 7 (4.1)
80 to 89 9 (11.8) 12 (12) 12 (7.1)
70 to 79 11 (14.5) 23 (23) 29 (17.1)
60 to 69 28 (36.8) 22 (22) 36 (21.2)
50 to 59 11 (14.5) 29 (29) 86 (50.6)
For comparison by chi-squared P < 0.0001 and P = 0.0015 (> 80% skewing); P < 0.0001 and P = 0.0034 (90+% skewing) for patients with 
rheumatoid arthritis (RA) and autoimmune thyroid diseases (AITDs), respectively.Page 2 of 8
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UK) with the respective normal ranges of 0 to 100 and 0 to 70
IU/mL.
The sera of RA patients obtained at the time of diagnosis were
examined for RF by nephelometry and for ACPA by ELISA
(second-generation test; Euro-Diagnostica, Arnhem, the Neth-
erlands).
X-chromosome inactivation study
Genomic DNA was extracted from 10 ml of peripheral blood
lymphocyte of patients and controls using standard methods
[16]. Genotyping of a polymorphic site in the androgen recep-
tor (AR) gene was performed and quantified to assess the XCI
patterns as described [17]. The degree of skewing was esti-
mated by an assay based on a methylation-sensitive HpaII
restriction site located in exon 1 of the AR gene. This site is
methylated on the inactive X, and unmethylated on the active
X-chromosome. When the genomic DNA is cleaved with HpaII
prior to PCR, only the methylated AR allele, which represents
the inactive X-chromosome, is amplified. A polymorphic CAG
repeat located within the amplified region is used to distin-
guish between the two alleles. For each patient and control
two separate PCRs, with or without HpaII treatment, were per-
formed using the same set of primers. Densitometric analysis
of the alleles was performed at least twice for each sample
using the MultiAnalyst version 1.1 software (Bio-rad, Hercules,
California, USA). A corrected ratio (CrR) was calculated by
dividing the ratio of the predigested sample (upper/lower
allele) by the ratio of the non-predigested sample for normali-
zation of the ratios that were obtained from the densitometric
analyses. The use of CrR compensates for preferential ampli-
fication of the shorter allele when the number of PCR cycles
increases [18]. A skewed population is defined as a cell pop-
ulation with greater than 80% expression of one of the AR alle-
les. This corresponds to CrR values of less than 0.33 or more
than three.
Statistical methods
The results from control and test groups in XCI studies were
compared by chi-squared test with Yate's correction. Fisher's
exact test was used when one cell had an expected count of
Figure 1
Distribution of X-chromosome inactivation patterns according to age in patients with rheumatoid arthritis.
Figure 2
Distribution of X-chromosome inactivation patterns according to age in patients with autoimmune thyroid diseases.Page 3 of 8
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count of less than five. P values of 0.05 or less were consider-
ate to be significant. Significance of P value was assessed
using a Bonferroni correction at 5% (a P value less 0.05/9 =
0.005) is considered significant.
Results
XCI status was found to be informative in 76 of the 106 RA
patients, 100 of the 145 AITDs patients and 170 of the 257
controls. Only those individuals whose alleles resolve ade-
quately for densitometric analysis were included in the study.
Skewed XCI (> 80% skewing) was observed in 26 of the 76
RA patients (34.2%), 26 of the 100 AITDs patients (26%), and
19 of the 170 controls (11.2%; P < 0.0001 and P = 0.0015).
More importantly, the frequency of extremely skewed XCI (>
90% skewing) was 22.4% (17 of 76) in RA and 14.0% (14 of
100) in AITDs. These frequencies are both significantly higher
than that of the control population, which is 4.1% (7 of 170; P
< 0.0001 and P = 0.0034; Table 1). Subdividing AITDs
patients according to clinical phenotype revealed that the fre-
quency of skewed XCI was 35% (14 of 40, P = 0.0001) and
20% (12 of 60, P = 0.04) in GD and HT, respectively. Con-
versely, stratifying RA patients according to RF status, ACPA
status, clinical manifestations (erosive disease and nodules)
and others autoimmune diseases did not reveal a statistically
significant difference (P > 0.05). Additionally, the comparison
according to geographic origin showed a skewed XCI of RA
patients compared with Tunisian controls (34.2% versus
19.5%; P = 0.03). However, difference was non-significant for
AITDs subgroup (P > 0.05).
Extremely skewed XCI have been reported in 1 to 2% of 20 to
40 year old women, and in 2 to 4% of 55 to 72 year old women
[19]. The data for RA and AITDs patients is strikingly bimodal,
we plotted the distribution of the X inactivation profiles accord-
ing to age. However, we did not observe a shift toward the
skewed range in older patients and controls (Figures 1, 2 and
3). Characteristics of the RA and AITDs patients with skewed
XCI are shown in Tables 2 and 3.
At the time of sample collection, 66 patients affected with RA
were being treated with immunosuppressive therapies (meth-
otrexate 10 to 15 mg once a week, n = 33; D-penicillamine
300 mg/day, n = 17; plaquenil 400 to 600 mg/day, n = 16).
Among 76 informative patients, 46 were received immunosup-
pressive agents (61%). A major concern with the observed
XCI patterns among RA patients was that concomitant immu-
nosuppressive therapy could influence the results, as has
been observed in feline hematopoietic cells [20]. Analysis of
the data on XCI patterns according to immunosuppressive
therapy did not reveal a statistically significant association
between RA patients treated with methotrexate and controls
(P = 0.52).
Discussion
The majority of human autoimmune diseases are characterized
by female predominance. RA and AITDs have a female:male
ratio of approximately 3:1 and 9:1, respectively [21]. Sex hor-
mone influences have been suggested to explain this phenom-
enon because the X-chromosome contains a considerable
number of sex and immune-related genes such as AR, IL2
receptor gamma chain, CD40 ligand and FOXP3 [22,23].
These genes are essential in determining sex hormone levels
and, more importantly, immune tolerance [24]. The contribu-
tion of genetics to sex differences in autoimmune diseases is
currently unexplored. An alternative explanation for the female
predominance has been recently proposed with the finding of
an enhanced skewed XCI in peripheral bloods cells of female
patients with autoimmune diseases [11-14]. The present
study tests the hypothesis that skewed XCI would be more
prevalent in females affected with autoimmune diseases than
in female control individuals. Therefore, we simultaneously
examined skewed XCI in 106 patients affected with RA and
145 patients affected with AITDs. The control group consisted
Figure 3
Distribution of X-chromosome inactivation patterns according to age control subjects. The control subjects were plotted according to geographic 
origin. Gray diamonds represent Tunisian controls and black diamonds represent Turkish controls.Page 4 of 8
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onstrated a significantly higher prevalence of extremely
skewed XCI in blood cell of females affected with RA and
AITDs compared with the control group (P < 0.0001; P =
0.0015, respectively), indicating a possible role of XCI in the
etiology of autoimmune diseases, and in the female prepon-
derance of RA and AITDs.
Skewed XCI was more commonly expected in peripheral
blood mononuclear cells due to the very high rate of turnover
of blood cells compared with other solid tissues [25]. Then,
we have examined XCI in peripheral blood mononuclear cells
of patients affected with RA and AITDs, and we found a higher
incidence of skewed XCI in those patients. We also tested the
relationship between XCI and AITDs phenotypes (GD and
HT). A skewed XCI was associated with both GD and HT (P
= 0.0001 and P = 0.04). Although, our results suggest the
involvement of XCI in female predisposition to RA and AITDs,
this hypothesis still to be confirmed in specific tissue, because
our analysis was performed in DNA from blood, and this may
Table 2
Characteristics of the patients with rheumatoid arthritis and skewed X-chromosome inactivation
Patient Birth date Disease onset Pregnancy history RF status ACPA status Other autoimmune 
disease
immunosuppressive 
therapy
90+% skewing
1 1949 48 G7, P4, A3 + + GSG MXT
2 1954 42 G5, P4, A1 + + - Plaquenil
3 1945 52 G7, P7, A0 - - GSG -
4 1946 40 G3, P2, A1 + - - -
5 1956 30 G2, P2, A0 - - - -
6 1946 40 G3, P2, A1 - + GSG -
7 1945 40 G4, P4, A0 + - - -
8 1945 39 G5, P5, A0 - + - -
9 1941 49 G7, P5, A2 + + - MXT
10 1947 49 G4, P3, A1 + - GSG -
11 1945 58 G4, P2, A1 - + GSG MXT
12 1950 40 G3, P2, A1 + + GSG MXT
13 1943 53 G3, P3, A0 + - - -
14 1961 35 G2, P1, A1 + - - -
15 1937 38 G4, P4, A0 - - - -
16 1941 45 G5, P3, A1 + + - -
17 1947 43 G3, P2, A0 - + GSG -
80 to 89% skewing
18 1959 42 G5, P5, A0 + + - MXT
19 1940 62 G0, P0, A0 - - - -
20 1938 60 G9, P8, A1 + + GSG MXT
21 1954 27 G0, P0, A0 + + GSG -
22 1957 37 G5, P5, A0 + + GSG -
23 1948 55 G9, P7, A0 + - - MXT
24 1948 55 G0, P0, A0 - - - -
25 1937 50 G3, P2, A1 - + GSG -
26 1985 14 G0, P0, A0 + - - -
A = spontaneous abortions; ACPA = anti-citrullinated protein/peptide antibodies; G = number of pregnancies; GSG = Sjögren's syndrome; MTX 
= methotrexate; P = para (pregnancies carried to term and delivered); RF = rheumatoid factor.Page 5 of 8
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[26,27] and there may exist locally skewed XCI in the thymus.
Moreover, this study can be complicated by existing differ-
ences in peripheral blood mononuclear cells constituents in
RA versus healthy controls. The XCI distribution in both Tuni-
sian and Turkish controls (Figure 3) according to age showed
that 19.5% (9 of 46) have a skewed XCI in Tunisian controls
which have a mean age of 43.5 years, whereas only 8% (10 of
124) in Turkish controls with a younger mean age (35 years).
This result suggests the importance of age in the difference of
XCI skewing.
Our results are in agreement with those reported by Ozçelik
and colleagues on 110 unrelated Turkish female AITDs
patients and 160 female controls that showed a greater pro-
portion of a skewed pattern of XCI (34%) than in controls (8%;
P < 0.0001) [13]. Indeed, supporting data have been reported
by Brix and colleagues, which assessed that the prevalence of
skewed XCI in female twins affected with AITDs was 34% but
Table 3
Characteristics of the patients with autoimmune thyroid diseases and skewed X-chromosome inactivation
Patient Birth date Disease onset Pregnancy history Diagnostic Auto antibodies
90+% skewing
1 1978 22 G1, P1, A0 HT +
2 1933 65 G11, P5, A0 HT +
3 1969 20 G1, P1, A1 HT +
4 1938 60 G3, P3, A0 GD +
5 1943 45 G2, P2, A0 GD +
6 1972 21 G2, P2, A0 HT +
7 1964 36 G2, P2, A0 HT +
8 1924 65 G9, P9, A0 HT +
9 1940 59 G10, P10, A0 HT +
10 1969 28 G4, P4, A0 GD +
11 1979 20 G0, P0, A0 GD -
12 1931 68 G13, P13, A0 HT -
13 1943 59 G1, P1, A0 GD -
14 1946 42 G2, P2, A0 GD -
80 to 89% skewing
15 1969 23 G2, P2, A0 HT +
16 1950 41 G3, P2, A1 GD +
17 1980 20 G0, P0, A0 HT +
18 1945 54 G4, P3, A0 HT +
19 1962 36 G7, P2, A5 HT +
20 1954 48 G3, P3, A0 GD +
21 1984 20 G0, P0, A0 GD +
22 1952 45 G2, P2, A0 GD -
23 1941 58 G5, P5, A0 HT -
24 1953 39 G2, P2, A0 GD -
25 1947 48 G1, P1, A0 HT -
26 1969 43 G2, P1, A1 GD -
A = spontaneous abortions; G = number of pregnancies; GD = Graves' disease; HT = Hashimoto's thyroiditis; P = para (pregnancies carried to 
term and delivered).Page 6 of 8
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(P = 0.004) [12-14]. Similar positive result was described in
other autoimmune diseases such as scleroderma [11]. In addi-
tion, our results are the first report that describes a significant
association between extremely skewed XCI and RA. Con-
versely, examination of XCI pattern of 58 Caucasian female
patients affected with multiple sclerosis, 46 with systemic
lupus erythematosus, 18 with juvenile RA and 45 with type 1
diabetes mellitus and 30 healthy women did not reveal skewed
XCI patterns [28]. Despite extensive efforts of XCI analysis in
different autoimmune diseases and populations, this hypothe-
sis remains to be confirmed because there is no apparent
autoimmunity directed against protein antigens encoded on
the X chromosome and the fact that, for many autoimmune dis-
eases, we found a female predominance in inbred mice mod-
els having two identical X chromosomes and therefore no
'foreign' antigens from the XCI [29].
In humans, it was reported that XCI process was genetically
controlled by genes located on X chromosome [30]. It has also
been suggested that genes on the X chromosome might show
linkage with AITD and RA [31,32]. Thus, the observed associ-
ation between skewed XCI and AITD and RA is not causal but
could be explained by linkage disequilibrium between mutation
responsible for XCI process and AITD and RA susceptibility
polymorphisms. In addition, numerous environmental risk fac-
tors such as tobacco smoking, hormones, diet, drugs, toxins
and/or infections are important in determining whether an indi-
vidual will develop autoimmune diseases [33]. In fact, environ-
mental agents are able to amplify autoimmunity in genetically
susceptible individuals and to break tolerance in genetically
resistant individuals, there by increasing the risk of developing
autoimmune diseases [34]. The interaction between genetic
and environmental factors remains to be achieved in order to
evaluate the involvement of each component in the develop-
ment of such autoimmune reactions.
Conclusions
We suggest a possible role of XCI mosaicism in the pathogen-
esis of RA and AITDs. However, the process of XCI needs to
be considered as a potential factor in the predominance of
females in most autoimmune diseases. It would also be of
interest first to study the XCI pattern in females affected with
other autoimmune diseases and second to test the XCI pat-
terns of many cell types.
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Evidence from autoimmune thyroiditis of skewed
X-chromosome inactivation in female predisposition
to autoimmunity
Tayfun Ozcelik*,1, Elif Uz1, Cemaliye B Akyerli1, Sevgi Bagislar1, Chigdem A Mustafa1,
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The etiologic factors in the development of autoimmune thyroid diseases (AITDs) are not fully understood.
We investigated the role of skewed X-chromosome inactivation (XCI) mosaicism in female predisposition
to AITDs. One hundred and ten female AITDs patients (81 Hashimoto’s thyroiditis (HT), 29 Graves’ disease
(GD)), and 160 female controls were analyzed for the androgen receptor locus by the HpaII/polymerase
chain reaction assay to assess XCI patterns in DNA extracted from peripheral blood cells. In addition,
thyroid biopsy, buccal mucosa, and hair follicle specimens were obtained from five patients whose blood
revealed an extremely skewed pattern of XCI, and the analysis was repeated. Skewed XCI was observed in
DNA from peripheral blood cells in 28 of 83 informative patients (34%) as compared with 10 of 124
informative controls (8%, Po0.0001). Extreme skewing was present in 16 patients (19%), but only in three
controls (2.4%, Po0.0001). The buccal mucosa, and although less marked, the thyroid specimens also
showed skewing. Analysis of two familial cases showed that only the affected individuals demonstrate
skewed XCI patterns. Based on these results, skewed XCI mosaicism may play a significant role in the
pathogenesis of AITDs.
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Introduction
Hashimoto’s thyroiditis (HD) and Graves’ disease (GD)
are autoimmune thyroid diseases associated with multiple
genetic factors. Although the pathogenesis is poorly
understood, a widely accepted model suggests an inherited
background, which predisposes the subjects to autoimmu-
nity. Additional intrinsic and extrinsic factors such as
hormones and the environment may ultimately trigger or
contribute to the development of the disease phenotype.1
Extensive linkage genome screens during the past decade
have resulted in the identification of several thyroid-
specific susceptibility genes and/or loci, but confirmation
through multiple population studies is still awaited for
the majority of these loci.1,2 A common feature of auto-
immune diseases, including autoimmune thyroid diseases
(AITDs), is an increased prevalence in women when
compared with men. The most striking sex differences are
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observed in AITDs, scleroderma, Sjo¨gren’s syndrome, and
systemic lupus erythematosus, which are diseases where
over 80% of the patients are females.3
It has been demonstrated that risk of autoimmunity
could be increased by a lack of exposure to self-antigens in
the thymus and the presence of autoreactive T cells.4 – 6
Disturbances in the X-chromosome inactivation (XCI)
process provide a potential mechanism whereby the lack
of exposure to self-antigens could occur,7,8 including
AITDs.9,10 X-chromosome inactivation is a physiologic
process that takes place in early female development and
results in the transcriptional silencing of one of the pair of
X chromosomes.11 As a result of this epigenetic regulation,
a random inactivation of the X chromosome inherited
from either parent occurs and normal female subjects
are thus a mosaic of two cell populations. It is therefore
an attractive hypothesis that skewed XCI could lead to
the escape of X-linked self-antigens from presentation in
the thymus or in other peripheral sites that are involved
in tolerance induction, inadequate thymic deletion, and
finally loss of T-cell tolerance. Indeed, we recently
observed skewed XCI in blood cells of women with
scleroderma.12
Based on our observation that an association exists
between skewed XCI and female predisposition to auto-
immunity, we hypothesized that skewed XCI may be
involved in the pathogenesis of AITDs, particularly in the
hematopoietic compartment. We observed extremely
skewed XCI in the blood samples of a significant propor-
tion of female patients with AITDs.
Methods
Patients and pedigree analysis
Caucasian women diagnosed with AITDs (n¼110), and
healthy female controls with no history of autoimmune
disease and cancer (n¼160) were included in the study.
Among the patients, 81 were diagnosed with HT and 29
with GD. The mean ages were 44.8714.1 (mean7SD) years
for AITDs (46714.2 years in the Hashimoto patients, and
40.6713.2 years in the Graves’ patients), and 46710 for
controls. The duration of the symptoms was 5.777.4 years
among the AITDs patients (5.777 years in the Hashimoto
patients and 678.5 years in the Graves’ patients). The
mean age of diagnosis was 39712 years. All of the patients
had attended the outpatient clinics of the Endocrinology
and Metabolic Diseases Department of Ankara University
School of Medicine for at least 1 year since the onset of
disease. Patients were randomly chosen for the study.
All clinical investigations described in this manuscript
were conducted in accordance with the guidelines in the
Declaration of Helsinki (http://www.wma.net). The ethics
review board of the participating institutions approved the
study protocol. Informed consent was obtained from all
subjects.
The diagnosis of HD was made by the existence of a firm
goitre in combination with elevated thyroid auto-anti-
bodies (thyroglobulin and/or thyroid peroxidase), a low
ultrasonographic echogenity of the gland, and demonstra-
tion of lymphocytic infiltration by fine-needle aspiration
biopsy and/or biochemical hypothyroidism. The diagnosis
of GD was based on biochemical hyperthyroidism, and a
diffuse symmetrical goitre in combination with positive
thyroid antibodies (thyroglobulin, thyroid peroxidase or
TSH receptor). In addition, thyroid ophthalmopathy and/
or diffuse hyperplasia on an isotope scan or ultrasonogra-
phy demonstrating homogenous echo texture may accom-
pany the clinical picture.
Following the XCI studies, a complete pedigree analysis
was carried out for 64 individuals informative for the AR
polymorphism with medical follow-up of reported AITDs
among family members when possible. Owing to emigra-
tion or unwillingness to contribute family information,
data could not be obtained from the remaining 19
participants. Family history of AITDs was determined by
reviewing the probands’ pedigree to determine the number
of relatives affected by these autoimmune diseases. Only
first- and second-degree relatives were counted. A positive
family history was noted if one additional AITD was
documented by medical review.
X-chromosome inactivation analysis
Genotyping of a highly polymorphic CAG repeat in the
androgen-receptor (AR) gene was performed to assess the
XCI patterns as described elsewhere.12,13 Densitometric
analysis of the alleles was performed at least twice for
each sample using the MultiAnalyst version 1.1 software. A
corrected ratio (CrR) was calculated by dividing the ratio of
the predigested sample (upper/lower allele) by the ratio of
the nonpredigested sample for normalization of the ratios
that were obtained from the densitometric analyses. The
use of CrR compensates for preferential amplification
of the shorter allele when the number of PCR cycles
increases.14 A skewed population is defined as a cell
population with greater than 80% expression of one of
the AR alleles. This corresponds to CrR values ofo0.33 or43.
Haplotype analysis
Human MapPairs Version 10 purchased from Research
Genetics (currently available by Invitrogen, CA, USA) was
used to screen the X chromosome. Site-specific PCR, 6%
polyacrylamide gel electrophoresis, and silver staining
techniques were used for genotyping the individuals. Gels
were manually pictured and genotyped. Cyrillic program
(version 2) was used to generate the haplotypes. A total of
27 X-chromosome-specific DNA markers from the Map-
Pairs Panel were genotyped. Map order and physical
positions (Mb) of the additional polymorphic DNA markers
were obtained from USCS genome browser (The University
of California Santa Cruz, CA, USA http://genome.ucsc.edu/).
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Statistical methods
The results from control and test groups in XCI studies
were compared by w2 test with Yate’s correction.
Results
PCR-based X-inactivation study of peripheral blood
XCI status was informative in 83 of the 110 AITDs patients
and in 124 of the 160 controls. Some heterozygous
individuals were considered uninformative since only
those whose alleles resolve adequately for densitometric
analyses were included in the study. Skewed XCI (480%
skewing) was observed in 28 of the 83 patients (34%), and
10 of the 124 controls (8%) (Po0.0001). When the data for
the two groups of AITDs patients was analyzed indepen-
dently, 23/67 (34.33%, Po0.0001) of the Hashimoto’s
patients and 5/16 (31.25%, P¼0.0167) of the Graves’
patients were found to display the skewed XCI in blood.
More importantly, extremely skewed XCI, defined as
490% inactivation of one allele, was present in 16 patients
(19%), and in only three controls (2.4%, Po0.0001) (see
Table 1). Extremely skewed XCI is a rare event in the
general population. It has been reported in only 1–2% of
women aged 20–40 years, and in 2–4% of women aged
55–72 years.15,16 The distribution of XCI skewing in the
general population is thought to be mainly due to chance
deviations from 50:50 as a result of the limited number of
embryonic cells present (4–20) at the time of XCI.17 Age
alone is unlikely to influence the strikingly bimodal data in
our AITDs patients (Figure 1). We did not observe a shift
towards the skewed range in older patients and controls.
PCR-based X-inactivation study of thyroid biopsy,
buccal mucosa, and hair follicle specimens
Thyroid biopsy, buccal mucosa, and hair follicle specimens
were obtained from five patients (04-121, 04-198, 04-214,
04-221, and 04-225). Their blood XCI profile displayed
almost exclusive representation of only one allele of the AR
polymorphism in their methylation-sensitive PCR assay,
which indicates extremely skewed XCI. Five randomly
selected patients showed skewing in the same direction for
all tissues, except hair follicle, that in the thyroid being less
marked than blood and buccal cells (Figure 2). Hair follicle
specimens had a random XCI pattern. The allele ratios are
given in Table 2.
Pregnancy history and pedigree analysis
Characteristics of the AITDs patients with skewed and
random XCI are shown in Table 3. Only those patients with
a complete pregnancy and family history are included in
this table. The pedigrees of many AITDs probands with
skewed XCI versus those with random XCI were interesting
in two aspects. First, recurrent spontaneous abortions
(defined as three or more pregnancy losses), which have
been shown to be associated with skewed XCI,16,18 occurred
in four of 25 (16%) of our AITDs probands with skewed
XCI. Conversely, a history of recurrent spontaneous abor-
tions was negative both in the patients with random XCI
and in the control group subjects (Po0.0199). Although the
etiology of recurrent abortions in thyroid autoimmunity
remains unknown, women who present with thyroid
antibodies in the first trimester of pregnancy have a two-
to four-fold increase in their miscarriage rates.19
Second, a positive family history, particularly in the
skewed group, was apparent (12/25, 48% in the skewed;
and 10/39, 25.6% in the random groups). We therefore
contacted all of the 12 probands in an attempt to extend
the X-chromosome inactivation studies to other family
members. Initially, a positive response was received from
three families, but blood samples could be obtained from
Table 1 Proportion of patients and controls with skewed
X-chromosome inactivation
Degree of
skewing (%) No. (%) observed with skewing
Autoimmune thyroiditis
(n¼83)
Control females
(n¼ 124)
90+ 16 (19.27) 3 (2.41)
80–89 12 (14.45) 7 (5.64)
70–79 6 (7.22) 22 (17.74)
60–69 16 (19.27) 29 (23.38)
50–59 33 (39.75) 63 (50.80)
For comparison by w2, Po0.0001 (480% skewing); Po0.0001 (90+%
skewing).
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Figure 1 Distribution of X-inactivation patterns according to age in
AITDs patients and control subjects.
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the family members of only two probands (04-445, Family
1; and 04-298, Family 2). An important observation
emerges from a study of these families: only the affected
individuals demonstrate skewed XCI patterns. For example,
XCI is extremely skewed in the affected sister and mother of
04-445 (Family 1), but random in the two unaffected sisters.
The inactive X chromosome here is of maternal origin. In
patient 04-298 (Family 2), skewing in the 80–89% range is
noted for her affected sister, but unfortunately her mother
was not informative for the AR polymorphism. Interest-
ingly, the inactive X chromosome appears to be of paternal
origin in Family 2 (Supplementary Figures 1 and 2).
Haplotype analysis
Because XCI segregates as a heritable trait associated with
the disease in two generations of Family 1, we performed
haplotype analysis by using polymorphic X-chromosomal
markers to determine possible segregation between the
Table 2 X-chromosome inactivation patterns in blood,
thyroid, buccal mucosa, and hair follicle specimens
Sample 04-121 04-198 04-214 04-221 04-225
Blood 94:6 91:9 84:16 92:8 91:9
Thyroid 72:28 79:21 76:24 74:26 64:36
Buccal 86:14 97:3 87:13 89:11 82:18
Hair 60:40 50:50 () 59:41 52:48
04-225
04-121
04-198
+- +- +-+
M Thy. biopsy Buccal Hair
04-214
04-221
Blood
-Hpa ll
Figure 2 X-inactivation analysis of androgen receptor locus. PCR
products of undigested () and HpaII-digested (þ ) DNA from
peripheral blood, thyroid biopsy, buccal, and hair follicle samples of
AITDs patients 04-121, 04-198, 04-214, 04-221, and 04-225 are
shown. Two alleles are seen in undigested samples, whereas a single
allele resulting from extremely skewed XCI is clearly visible in all
peripheral blood samples. Allele ratios are given in the text and in
Table 2. M: marker (pUC mix 8), 331 and 242 bp fragments are visible.
Table 3 Characteristics of the patients who are informative for X-chromosome inactivation status
Patient Birth date Disease onset Pregnancy history Sex and birth date of children Family history of first-degree relatives
90+% skewing
1 04-136a 1975 2004 G0,P0,A0 () ()
2 04-127b 1975 2003 G0,P0,A0 () ()
3 04-138b 1962 1980 G7,P0,A7 () Two sisters
4 04-298b 1979 2003 G1,P1,A0 F03 Mother, one sister
5 04-445b 1961 2000 G1,P1,A0 F88 Mother, one sister
6 04-198b,c 1935 2004 G2,P2,A0 M68,M72 ()
7 04-221b,c 1958 2000 G4,P2,A2 M91,F94 Two sisters
8 04-250b 1967 1996 G7,P2,A5 M89,M93 One son
9 04-226b,c 1963 2004 G3,P3,A0 M83,F88,M98 One sister
10 04-233a 1967 1990 G4,P3,A1 M88,F94,M01 ()
11 04-121b,c 1957 1988 G7,P4,A3 F78,M83,F91,F94 ()
12 04-205b 1927 2003 G6,P5,A1 M47,M50,F52,F53,M55 ()
13 04-225b,c 1936 1975 G6,P6,A0 F56,F58,F60,F62,M64,M66 One daughter
80–89% skewing
14 04-132b 1960 2002 G0,P0,A0 () Mother, one sister
15 04-223b 1956 1988 G0,P0,A0 () Mother, one sister
16 04-105a 1978 1999 G5,P1,A4 M98 ()
17 04-131b 1944 2002 G3,P2,A0 M69,M71 ()
18 04-120b 1956 1994 G3,P3,A0 F75,M77,F78 ()
19 04-107b 1948 1998 G4,P3,A1 F70,F72,F76 ()
20 04-98b 1956 2000 G8,P3,A1 F79,F81,F87 Two daughters
21 04-218b 1941 1991 G4,P3,A1 M61,F63,F67 ()
22 04-108b 1952 1999 G5,P3,A2 F77,F78,M83 ()
23 04-208b 1960 1999 G5,P3,A0 F83,F85,M88 Mother
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disease and marker alleles. Although the size of this family
is not large enough to prove linkage, it still provides
valuable information about the exclusion area on the X
chromosome. This helps to define a minimal critical region
on the X chromosome, which might be associated with
AITDs. Xp11-q13 (GATA144DO4, DXS7132, and AR) and
Xp22 DNA markers (DXS8022, DXS987, and DX9902)
showed concordance among the affected individuals
indicating positive segregation between the disease and
marker alleles. The haplotype structure is shown in
Figure 3. However, lod score20 analysis did not allow
formal acceptance of linkage to any loci mainly due to the
small size of the family.
Discussion
The autoimmune diseases include more than 70 chronic
disorders that affect approximately 5% of the population. A
reduction in sex ratio (male:female) is characteristic of
most such diseases, including AITDs.3 Even though the
Table 3 (Continued)
Patient Birth date Disease onset Pregnancy history Sex and birth date of children Family history of first-degree relatives
24 04-110a 1960 1998 G4,P4,A0 M80,M83,M85,F96 ()
25 04-214b,c 1921 1999 G9,P8,A1 F44,M45,F47,F48,M54,F56,F58,M60 One daughter
70–79% skewing
26 04-203b 1961 2004 G3,P1,A0 M82 ()
27 04-230b 1951 1999 G2,P2,A0 M77,M86 One son
28 04-213b 1947 1998 G7,P3,A0 F67,M68,M71 ()
29 04-228b 1953 2001 G3,P3,A0 M71,M73,M82 ()
30 04-137b 1932 1981 G5,P4,A0 F50,F53,M55,F59 ()
60–69% skewing
31 04-206a 1946 1964 G1,P0,A1 () ()
32 04-92b 1971 1998 G3,P1,A0 F96 Mother
33 04-240b 1975 2003 G2,P1,A0 M00 ()
34 04-139b 1959 2002 G1,P1,A0 M97 ()
35 04-257b 1973 2004 G3,P2,A1 M95,M01 ()
36 04-112b 1952 1999 G2,P2,A0 F72,F77 Mother
37 04-220a 1955 1998 G3,P2,A0 M74,M78 ()
38 04-103b 1962 1986 G6,P2,A1 F82,M92 ()
39 04-251b 1941 1984 G5,P3,A1 M60,M63,M65 Two sisters
40 04-99b 1961 1997 G6,P3,A2 F81,F85,F87 Mother, one sister
41 04-224a 1950 2001 G6,P5,A1 M69,M72,F73,M75,F78 ()
50–59% skewing
42 04-96b 1939 1996 G0,P0,A0 () ()
43 04-242b 1960 1999 G0,P0,A0 () ()
44 04-129b 1982 1998 G0,P0,A0 () Mother
45 04-196b 1956 1999 G6,P1,A0 F93 ()
46 04-231b 1964 2003 G1,P1,A0 M93 ()
47 04-201a 1971 2001 G2,P1,A1 F93 Mother
48 04-95b 1975 2004 G3,P2,A0 F98,M00 ()
49 04-239b 1951 2003 G3,P2,A0 M68,M75 ()
50 04-246b 1961 1996 G2,P2,A0 M78,F81 ()
51 04-200b 1954 1992 G5,P2,A0 M73,M75 Three sisters
52 04-237b 1970 2004 G2,P2,A0 M93,F97 ()
53 04-102b 1964 2003 G3,P2,A1 F95,F87 ()
54 04-204b 1949 2002 G4,P2,A0 F71,M73 ()
55 04-93a 1960 2003 G2,P2,A0 M91,F94 ()
56 04-116a 1960 2003 G4,P2,A0 F86,M89 One brother
57 04-197b 1961 1976 G6,P3,A2 M82,M84,M98 ()
58 04-229b 1938 1980 G3,P3,A0 M61,M63,F65 One sister
59 04-255b 1974 1993 G3,P3,A0 F92,M96,F01 ()
60 04-212a 1958 2002 G4,P3,A0 M76,F80,M84 ()
61 04-238b 1939 2002 G6,P4,A0 M61,M65,F67,M72 ()
62 04-117b 1944 2004 G6,P4,A0 M60,M64,F66,F67 ()
63 04-211a 1950 2002 G6,P6,A0 F66,F67,F72,M84,M85,M86 ()
64 04-243a 1937 1994 G12,P7,A1 M57,M59,F60,F62,M65,M67,F68 ()
G, number of pregnancies; P, para (pregnancies carried to term and delivered); A, spontaneous abortions.
aGraves’ disease.
bHashimoto’s thyroiditis.
cPatients from whom thyroid biopsy samples were obtained.
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female prevalence of autoimmune diseases has been
recognized for over a hundred years, candidate mecha-
nisms that could be important in pathogenesis have been
uncovered only during the past two decades. These include
genetic traits associated with autoimmunity,21 pregnancy-
related microchimerism,22 and disturbances in XCI mosai-
cism in female subjects.12 In this study, we demonstrate
skewed XCI patterns in peripheral blood mononuclear cells
of a significant proportion (34%) of female subjects with
AITDs. Approximately 8% of female control subjects
demonstrate skewed X-inactivation patternsX80:20, which
is consistent with previous estimates.16,18,23 The effect is
more pronounced at patterns of X-inactivation X90:10;
nearly 20% of AITDs patients show such skewing (Supple-
mentary Figure 3), compared with only a few percent of
female control subjects. Our results show that factors
associated with extremely skewed XCI could account for a
significant proportion of female patients with AITDs.
Skewed XCI is a result of primary or secondary causes.
The former is bias in the initial choice of which X
chromosome is inactivated due to germline XIST (X-
inactive-specific transcript) mutations.24 The secondary
causes are deleterious X-linked mutations, X chromosome
rearrangements, aging, twinning, or monoclonal expan-
sion of cells (for a review, see Brown25). We believe that
deleterious X-linked mutations or X chromosome rearran-
gements and their differential expression patterns could
provide a disadvantage to blood and buccal cells, and
possibly to thyroid cells in AITDs patients, and lead to
skewed XCI. This has been supported by our observation
that maternally inherited skewed XCI profile accompanies
the disease phenotype for our AITDs Family 1. We observed
segregation between the disease and marker alleles with
the DNA markers residing on the distal short arm and
pericentromeric regions of the X chromosome in this
family. Although examples of skewed X-inactivation
segregating with a trait have been reported previously,18,26
this is the first example in AITDs to the best of our
knowledge. In a recently published study on a three-
generation kindred, extreme skewing of X inactivation was
documented in three female subjects who have hemophilia
A.26 Since the inactive X was always of paternal origin
in affected female subjects, the authors concluded that
skewing in the family resulted from an abnormality in the
initial choice process. This prevented the X chromosome,
which carried the mutant FVIII allele, from being an
inactive X. In our Family 2 with two affected sisters, the
inactive X chromosome was of paternal origin like the
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Figure 3 Haplotype structure of Family 1. Patient 04-445 was
arbitrarily selected to construct the haplotype. Maternally inherited
haplotype was highlighted with solid black bar. Haplotypes of the
remaining sibs were compared with the reference individual (04-445),
and shared portions were also marked with solid bars. Noninforma-
tiveness in the crossover regions were demonstrated with thin bars.
The regions between the DNA markers DXS8051 and DXS8036 as well
as DXS8014 and AR regions on Xp22 and Xp11-q13 regions,
respectively, were not excluded since positive segregation between
the disease and marker alleles was observed.
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hemophilia A family. Extension of both the XCI and
linkage studies to large cohorts with familial AITDs cases
could prove to be very rewarding in understanding the
relation between skewed XCI and autoimmune thyroidites.
Studies that aim to delineate the medical consequences
of skewed X-inactivation have shown that clinical mani-
festation of X-linked disorders in female subjects could be
influenced by disturbances in the XCI process.27 In
addition, it has been hypothesized that skewed XCI could
be a factor that influences female predisposition to
autoimmunity.7,8 Now that we have demonstrated skewed
patterns of XCI in a significant proportion of female AITD
patients, deviation from the physiological range of XCI
mosaicism could be considered as a potential mechanism
contributing to disease pathogenesis. This is further
supported by the recently reported observation that female
twins with AITDs have a high frequency of skewed XCI.28
Although extremely skewed XCI is rare, it does not
always lead to the development of AITDs. A subsequent
event, such as environmental exposure to viral, chemical,
or other agents may trigger a cascade that results in AITDs.
In addition, the co-inheritance of genetic susceptibility
factors, such as functional variants in vital negative
regulatory molecules of the immune system,29,30 may
exacerbate the effects of skewed XCI and contribute to
the development of autoimmune diseases including AITDs.
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